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Studies suggest antiretroviral therapy (ART) use during pregnancy may be associated with adverse 
pregnancy outcomes.  Given the large numbers of pregnancies exposed to ART, better understandings of 
potential associations with commonly used ART regimens and adverse pregnancy outcomes is critical.  
With the number of women on ART initiated before conception rapidly increasing, understanding how 
current recommended regimens and timing of ART initiation may influence pregnancy outcomes is critically 
important. 
Methods 
This mini-dissertation presents a research protocol (Section A), literature view (Section B) and journal-
formatted manuscript (Section C) for a study of ART use and birth outcomes among HIV-infected women 
and a comparator cohort of HIV-uninfected women. Pregnant women seeking care at the Gugulethu MOU, 
a primary-level antenatal care facility in Cape Town, South Africa were enrolled between March 2013 and 
August 2015.  Pregnancy dating was based on research ultrasound, or last menstrual period/clinical exam 
where ultrasound was unavailable.  Women were followed from their 1st antenatal visit through delivery. 
Analyses compared birth outcomes (preterm (PTD), low birthweight (LBW) and small for gestational age 
(SGA) deliveries) between HIV-infected and uninfected women; and between women on ART initiated 
before conception versus those initiating ART during pregnancy.   
Results 
In 1554 women with live singleton births (mean birthweight, 3079g; 21% preterm; 13% LBW; 12% SGA), a 
higher prevalence of PTD (22% vs 13%, p=0.001) and LBW (14% vs 9%, p=0.030) were observed in the HIV-
infected compared to HIV-uninfected women.  Adverse birth outcomes (PTD, LBW and SGA) did not vary 
systematically among the HIV-infected women regardless of ART initiation timing (initiated ART before 
conception or initiated ART to during pregnancy).  The absence of associations between the adverse birth 
outcomes and timing of ART initiation persisted after adjusting for maternal age, parity, height, CD4 cell 
count and viral load at 1st visit. 
Conclusions 
Levels of adverse birth outcomes, in particular PTD, remain high among HIV-infected women, however our 
findings from a routine care cohort demonstrate that the timing of initiation of widely used regimens 
before conception or during pregnancy do not appear to be associated with an increased risk in adverse 
pregnancy outcomes. 
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Antiretroviral therapy (ART) is a principal intervention ensuring maternal and child health in the 
context of HIV infection.  World Health Organisation (WHO) recommends the use of ART for all HIV-
infected women during pregnancy and breastfeeding, regardless of CD4 cell count or WHO disease 
stage, to be continued as lifelong treatment (Option B+) (1).   
 
In South Africa and other similar low and middle-income countries (LMIC), large and increasing 
proportions of HIV-infected pregnant women are accessing ART – increasing the number of fetuses 
exposed to antiretroviral (ARV) drugs during their early developmental stages.  With this increased 
ART use during pregnancy, concern has been raised about the possibility of adverse birth outcomes 
(preterm delivery (PTD), low birth weight (LBW) and small-for-gestational age (SGA)), associated with 
in utero ART exposure; with no consensus about the effect on these birth outcomes.  Untreated, 
advanced HIV disease has already been shown to be associated with these adverse birth outcomes 
(2, 3).  The effect of ART on adverse birth outcomes adds further complexity to deciphering the 
relationship between HIV infection, ART use and birth outcomes. 
 
The first reports linking adverse birth outcomes to ART came from European studies showing an 
association between ART exposure and both PTD and LBW (4, 5).  Associations were less clear in 
American studies, with some of these studies only finding associations with protease inhibitor (PI) -
based regimens (6, 7).  Although a number of studies in different settings have investigated the 




Several factors have been proposed as explanations for the apparently conflicting conclusions.  First, 
a frequently hypothesized explanation pertains to heterogeneity in study populations.  Most studies 
have been conducted in high income countries; however the majority of women requiring ART in 
pregnancy are in LMIC, where the impact of adverse birth outcomes is greater, owing to insufficient 
obstetric and neonatal services.  Study populations in different settings are also likely to differ in 
terms of risk factor prevalence and background rates of adverse birth outcomes. 
 
Second; different methodological approaches complicate comparisons of individual studies, with the 
choice of comparison groups used in the studies usually dictated by available data or the current 
treatment guidelines.  HIV treatment and practice guidelines in pregnancy have shifted over time, 
towards more effective regimens and longer periods of antenatal ART coverage.  The resulting use of 
different regimens and timing of initiation, depending on the setting, impacts on comparisons.  
Additionally, data is mostly available from high income countries where ART initiation occurred 
regardless of HIV disease stage, and regimens were primarily PI-based because of their tolerability in 
pregnancy.  Less data has been generated from LMIC, particularly Africa, which carries a significant 
burden of the disease.  Studies in sub-Saharan Africa (SSA) suggest an association between ART and 
risk of PTD/LBW (8, 9); as well as increased risk of stillbirth, PTD, SGA and early neonatal death (10).  
However, regimens used in these studies did not include the current WHO recommended first-line 
regimen (tenofovir (TDF) + lamivudine (3TC)/emtricitabine (FTC) + efavirenz (EFV)).  Recent reports 
from a national program in which pregnant women were initiated on TDF+FTC+EFV suggested no 
increased risk of adverse birth outcomes when compared to other commonly used PMTCT regimens 
including zidovudine (ZDV) monotherapy (11).  This is reassuring following concern raised by results 
of the PROMISE study, which reported more severe adverse birth outcomes among women initiated 
on triple drug regimens compared to ZDV monotherapy (12).   
 
Third, differences in study design and implementation are directly related to the type and quality of 
data collected.  Differences or compromises in outcome ascertainment methods in the different 
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studies, through the use of imprecise assessment methods for birthweight (abstraction of clinic 
records) and gestational age (menstrual history and clinical examinations) determination, can affect 
the detection of the magnitude of associations.  Additionally, the degree of potential measurement 
error of the exposures, outcomes and/or risk factors can also be affected.  Unmeasured or 
inaccurately measured risk factors compromise the controlling of their effects resulting in residual 
cofounding.  The non-random allocation and misclassification of exposures (timing of ART initiation 
or type of regimen), particularly in observational studies, can result in reductions in power and 
decreased likelihood of detection of true associations.  Consequently, limiting measurement error 
through the use of robust measures with fewer errors in future studies is vitally important.  
Given these challenges, more data are required to elucidate the relationship between ART and 
adverse birth outcomes.  Additionally, the local background rates of adverse birth outcomes are 
often unknown, so more studies including HIV-uninfected comparators are required.  Given the 
increasing population of HIV-infected pregnant women in our setting, we aim to investigate birth 
outcomes in a well characterized population of pregnant women undergoing routine antenatal care 
(ANC) using commonly used regimens at a large public sector primary care facility in Cape Town, 
South Africa. 
1.2. Rationale 
Whilst there is indisputable benefit of ART to both mother and infant, evidence indicating that ART 
use during pregnancy could play a role in increasing the risk of adverse birth outcomes has raised 
concern.  Data from Africa, where most ART use in pregnancy occurs, is limited by the poor quality of 
pregnancy dating as well as limited data on the effects of the most commonly used non-nucleoside 
reverse transcriptase (NNRTI)-based regimens.  Consequently, further research is required in 
countries such South Africa, which has the largest treatment program with 3.4 million people on ART 
(13), because of the far reaching implications for infant morbidity and mortality.  Findings from a 
randomized control trial (RCT) in Botswana demonstrated that HIV-exposed preterm infants 
(compared to term infants) had a 5-fold increased risk of death and higher rates of severe lower 
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respiratory tract infections (8).  Additionally PTD, LBW and SGA have long term consequences for 
child development, educational attainment (14), and quality of life.  In view of these long term 
consequences of adverse birth outcomes it is essential to quantify their associations with ART use in 
high prevalence LMIC in order to facilitate risk-benefit assessment of ART and the different regimens 
(15).  
 
2. AIMS AND OBJECTIVES 
2.1 Aim 
The aim of the proposed study is to examine the association between ART use and birth outcomes in 
a population of pregnant women undergoing routine ANC at a large public sector primary care 
facility in Cape Town, South Africa.  
2.2 Objectives 
1. To describe the clinical and demographic characteristics of pregnant women seeking ANC. 
2. To describe the prevalence of adverse birth outcomes (PTD, LBW and SGA) among pregnant 
women booking for ANC. 
3. To examine the association between adverse birth outcomes among pregnant women seeking 
ANC by (i) HIV status (i.e comparing HIV-infected vs HIV-uninfected) and (ii) Timing of ART 
initiation (i.e comparing ART Initiation before conception vs ART initiation during pregnancy). 
 
3. METHODS 
3.1 Study Design 
The proposed study will be a sub-study of the MCH-ART trial, a community-based study of 
antiretroviral services for HIV-infected women during pregnancy and postpartum 
(https://clinicaltrials.gov/ct2/show/NCT01933477).  The MCH-ART trial has been described in detail 
elsewhere (16); however in brief the primary objective of this multicomponent trial was the 
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comparison between the maternal-and-child health focused ART services and the general adult ART 
services during the postpartum period.  Phase 1 was a cross-sectional evaluation of consecutive HIV-
infected women and the primary aim of this phase was the characterization of the health status of 
HIV-infected pregnant women, including maternal and infant outcomes. 
Analysis for this proposed study will draw on data collected between March 2013 and August 2015 
during the first phase of MCH-ART as well as a comparator cohort of HIV-uninfected women.  
 
3.2 Study Setting 
The setting for parent study was the Gugulethu Midwife Obstetric Unit (MOU), a primary care facility 
in the peri-urban area of Gugulethu in Cape Town, South Africa.  The MOU provides antenatal and 
obstetric care for low-risk pregnancies; women with history of pregnancy complications or those 
requiring specialist review and/or intervention are referred to secondary (Mowbray Maternity 
Hospital) or tertiary (Groote Schuur Hospital) obstetric facilities.  The catchment population of the 
MOU is approximately 350 000 and uptake of ANC services is very high in this population with 
coverage consistently reported at greater than 95% (17).  In 2014 the antenatal HIV seroprevalence 
at the MOU was estimated at 30% (17).  PMTCT services are integrated into ANC services resulting in 
near universal routine HIV testing in pregnancy using HIV rapid antibody tests.  All women without a 
previous HIV diagnosis undergo HIV counselling and testing at their first ANC visit.  Women who test 
HIV negative are retested prior to or at delivery.   
 
During the study period, women who tested positive and had a CD4 cell count <350 cells/µl or WHO 
clinical stage 3 or 4 conditions were eligible to initiate ART during pregnancy for maternal treatment.  
In July 2013, local PMTCT guidelines changed to recommend initiation of triple-drug ART for all HIV-
infected pregnant women regardless of CD4 cell count (Option B+).  ART primarily consisted of a 
fixed dose combination of TDF+FTC+EFV as first-line therapy for the majority of HIV-infected 
pregnant women initiating ART.  
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3.3 Study Population and Sampling 
Pregnant women seeking ANC services at the Gugulethu MOU between March 2013 and August 
2015 enrolled in the parent study and the comparator cohort (HIV-uninfected) will be included.  
Inclusion Criteria 
 Aged 18 years or older  
 Enrolled into parent study 
 Confirmed pregnancy according to urine pregnancy test, ultrasound or clinical assessment 
 
3.4 Data Collection  
Data collected during the parent study will be used for this proposed study.  This data was collected 
using standardized questionnaires as well as the review of medical and laboratory records.  
 
3.4.1 Enrolment Questionnaires 
In the parent study, the standardized questionnaires completed by all enrolled women, 
included maternal demographics and medical history (Appendix 1A).  For the enrolled HIV-
infected women, additional data was collected on current ART use based on self-report and 
previous antiretroviral exposure (Appendix 1B).   
 
3.4.2 Medical Record Review 
Data abstracted, during the parent study, from clinical and obstetric records of enrolled 
women following their first antenatal visit and discharge from the postnatal ward will also be 
used for the proposed study (Appendices 1C and 1D).  Information abstracted includes 
maternal physical examination data (height and weight), results of routine blood tests (Hb, 
syphilis screening, ABO blood group), HIV status and maternal diagnoses during pregnancy 
and delivery.  For the enrolled HIV-infected women additional data abstracted from PMTCT 
records includes date of diagnosis, CD4 cell count and viral load (VL) enumeration, dates and 
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types of antiretroviral drugs received.  Antiretroviral regimen data used in the proposed 
study will be a combination of the self-reported ART use and abstracted information.   
Infant data abstracted from infant medical records will also be used for the proposed study 
and this includes birth outcome, gender, birthweight and any delivery complications.   
 
3.4.3 Gestational Age Measurement 
To determine gestational age (GA), all enrolled participants had an obstetric ultrasound (US) 
conducted by an experienced research sonographer using standardized assessment 
protocols.  In most cases, the estimated GA was calculated based on this ultrasound 
determined estimated delivery date (EDD), however in cases where the GA seemed 
implausible and last menstrual period (LMP) was known, LMP EDD was used.   
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Table 1.  Variables to be included in the analysis 
Variable Scale Categories 
Maternal Characteristics 
Age (years) Numerical - Continuous Quartile Category Proportions 
Categorical - Ordinal <24, 25-29, >30 
Education Categorical - Binary Finished high school, Did not finish high school 
Employment Status Categorical - Binary Employed, Not Employed 
Socio-economic Status Categorical - Ordinal Lowest, Medium, Highest 
Obstetric Characteristics 
Gestation at Booking (weeks) Numerical - Continuous Quartile Category Proportions 
Maternal Height (cm) Numerical - Continuous Quartile Category Proportions 
Categorical - Ordinal <155, 156-161, >162 
Gravidity Numerical - Discrete Quartile Category Proportions 
Categorical - Ordinal 1, 2, >3 
Parity Numerical - Discrete Quartile Category Proportions 
Categorical - Ordinal 0, 1, >2 
Previous Miscarriage Numerical - Discrete Quartile Category Proportions 
Previous Preterm Numerical - Discrete Quartile Category Proportions 
HIV 
ART Regimen Categorical - Nominal TDF+3TC+EFV, TDF+3TC+NVP, Other NNRTI-based, 
PI-based regimen 
CD4 (cells/µl) Numerical - Continuous Quartile Category Proportions 
Categorical - Ordinal <200, 201-350, 351-500, >500 
Viral Load (log10 copies/ml) Numerical – continuous log (10) Quartile Category Proportions 
HIV Status Categorical - Binary HIV-infected, HIV-uninfected 
ART Initiation Status Categorical - Binary Initiated before conception, initiated during pregnancy 
Obstetric Outcomes 
Gestational Age at delivery 
(weeks) 
Categorical - Ordinal Term (>37), Preterm (<37) 
Late Preterm (34-37), Moderately Preterm (32-34), 
Very Preterm (28-32) 
Birthweight (grams) Numerical - Continuous Quartile Category Proportions 
Categorical - Ordinal Normal (>2500), Low Birthweight (1500-2500) 
Very Low Birthweight (<1500) 
Size for Gestational Age Categorical - Ordinal Large (LGA), Appropriate (AGA), Small (SGA) 
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3.5 Outcomes of Interest  
The main outcomes of interest are adverse birth outcomes, and this will include pregnancy loss, PTD, 
LBW and SGA.  These outcomes will be estimated within each stratum of the exposure variable and 
compared using odds ratios obtained from regression modelling.  Definitions and classifications of 
outcome variables will be as follows: 
 
3.5.1 Pregnancy Loss 
These will include ectopic pregnancies, miscarriages and stillbirths.  Ectopic pregnancies will 
be determined by the research sonographer.  Miscarriages will be defined as pregnancy loss 
<28 weeks and stillbirths will be defined as fetal death occurring before/during labour and 
birth based on a 1 minute APGAR score of 0 (17).  
 
3.5.2 Preterm Delivery (PTD) 
Preterm delivery will be defined as delivery <37 weeks’ gestation.  Preterm infants will be 
categorized as late preterm (34-37 weeks), moderately preterm (32-34 weeks) and very 
preterm (<32 weeks). 
 
3.5.3 Low Birth Weight (LBW) 
Low birthweight will be defined as infants with a birth weight <2500g and very low 
birthweight (VLBW) as <1500g. 
 
3.5.4 Small for Gestational Age (SGA) 
Size for gestational age will be based on INTERGROWTH-21st Project Standards.  Infants with 
birthweights <10th percentile for their gestational age will be classified SGA and infants 
between 10th – 90th percentile, appropriate for gestational age (AGA). 
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3.6 Exposure of Interest  
The exposure of interest is HIV/ART status and this will be categorized as: 
 No ART (HIV-uninfected women) 
 ART initiated before conception   
 ART initiated during pregnancy  
 
Among the women who initiated ART during pregnancy there will be a further subdivision according 
to the gestational age at ART initiation 
 First trimester (<14 weeks) 
 First half of second trimester (14-20 weeks) 
 Second half of the second trimester (21-27 weeks) 
 Third trimester (≥28 weeks) 
 
ART regimens used by enrolled women will be categorized according to regimen classes as either PI 
or NNRTI.  NNRTI regimens will be categorized as EFV-based, nevirapine-based (NVP) or other 
NNRTIs. 
 
3.7 Data Management and Analysis Plan 
3.7.1 Data Management  
Data collected during the course of the parent study has been entered into a customized 
study Microsoft Access database, which is maintained in a firewall-protected UCT server with 
nightly backups.  This database is password-protected following standard password safety 
procedures.  All study records contain anonymous participant identification numbers, and no 
participant names or identifiers are recorded.  The data used for this analysis will be stored 
on a password protected personal computer that can only be accessed by the researcher. 
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3.7.2 Data Analysis  
All statistical analyses will be conducted using STATA Version 14 (Stata Corporation, College 
Station, Texas USA).  Continuous variables will be summarized using either the mean and 
standard deviation (SD) for normal distributed variables; or the median and the interquartile 
range (IQR) for non-normal distributed variables.  Categorical variables will be described 
using proportions.   
 
Analyses will focus on three exposure comparisons: HIV-infected versus HIV-uninfected 
(Comparison A); among HIV-infected women, those initiating ART before conception versus 
those initiating ART during pregnancy (Comparison B); and among women initiating ART 
during pregnancy across gestational ages at ART initiation (Comparison C). 
Descriptive statistics will be used to describe the overall prevalence of the adverse birth 
outcomes (PTD, LBW and SGA) across the exposure groups.  For continuous variables either 
parametric (t-test or ANOVA) or non-parametric tests (Wilcoxon Sign Rank or Kruskal Wallis) 
will be used to test for associations; while chi-squared and rank-sum tests will be used to test 
for associations between categorical variables.  Regression modelling will be used to 
estimate the association between HIV/ART status and the adverse birth outcomes of 
interest.  A priori confounders will include age, maternal height, parity and previous PTD; and 




The University of Cape Town Faculty of Health Sciences Research Ethics Committee (UCT-HREC; REC 
REF: 451/2012) (Appendices 2A and 2B); and the Columbia University Medical Center Institutional 
Review Board (CUMC-IRB) (Appendix 2C) approved the parent study.  Additionally, permission to 
conduct the parent study was granted by the research oversight body of the Provincial Government 
of the Western Cape Department of Health (Appendix 2D).  Ethical approval for this proposed study 
will be sought from the UCT-HREC. 
4.1 Informed Consent 
All women deemed eligible and who agreed to participate in Phase 1 of the parent study completed 
a written informed consent form (Appendix 3A).  In consenting to participate in the study, 
participants gave permission for the abstraction of data from their routine clinical records through 
the pregnancy and post-partum period.  As part of this proposed study, pre-existing data collected 
from the enrolment questionnaires and abstraction clinical and obstetric records will be accessed 
and utilized in accordance with the consent received from phase 1 participants.  Given that no direct 
contact with participants will be required for this study, we will not obtain informed consent from 
individual participants.   
4.2 Privacy and Confidentiality 
The following provisions were made to minimize the risk of loss of confidentiality during the course 
of the parent study: 
 All staff involved in the collection and management of data underwent training on their ethical
obligations to ensure participant confidentiality
 As per standard practice, participants were identified by anonymous identifiers used on all
study documents.  Participant names only appear on the informed consent and locator tracer
documents and these documents were kept separate from participant study documents.
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 All study related documents were kept in a locked cabinet at UCT  
 All databases were password protected and maintained in a firewall protected UCT server 
 
During the proposed study no personal identifiers will be present in the data used for analysis, 
participants will be identified by the anonymous identifiers assigned in the parent study.  
Additionally, the results of the proposed study will not report on individual participants ensuring 
confidentiality. 
 
4.3 Risks and Benefits 
A description of risks and benefits, reimbursement details of the parent study have been provided 
and approved previously (HREC REF: 451/2012).   
 
4.3.1 Risks 
Participants are considered to be at minimal risk in this proposed study, with the only 
potential risk being the loss of confidentiality.  Measures have previously been implemented 
to minimize the possibility of these risks as noted above.  
 
4.3.2 Benefits 
Participants will not derive any direct benefit from this proposed study as it is a retrospective 
analysis of previously collected data.  There will however be considerable indirect benefit to 
the community of HIV-infected pregnant women in Cape Town, South Africa and other LMIC.  
Current HIV treatment guidelines recommend lifelong ART for all HIV-infected pregnant 
women, and understanding the long term impact of this in vitro ART exposure on infants and 
children of exposure to HIV and ART during pregnancy and breastfeeding will be beneficial to 
health care providers and maternal and child health.  
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4.4 Reporting and Implementation 
Upon completion of the analysis, the results of this proposed study will be submitted to an 
appropriate peer-reviewed journal agreed upon in collaboration with the relevant stakeholders.   
These results will also be presented at appropriate local and international conferences, workshops or 
meetings as well as to the staff at the Gugulethu MOU. 
 
4.5 Logistics 





Dec 16 Jan 17 Feb 17 Mar 17 
Merge, clean and check data sets     
Analysis     
Prepare draft manuscript     
Prepare final manuscript and submit for 
publication 
    
 
4.6 Budget 
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1. INTRODUCTION 
Significant progress has been made globally in the reduction of child mortality since 1990.  There has 
been a global decline in under-5 deaths from 12.7million in 1990 to 5.9 million in 2015 (1).  Preterm 
delivery (PTD) is the second major cause of these under-5 deaths, and the single most important 
direct cause of death in the critical neonatal period (2).  Low birth weight (LBW), which is generally 
recognized as having short- and long-term consequences, is also an indirect cause of neonatal 
deaths.  The global prevalence of LBW is estimated to be 15.5%, which translates into 20 million LBW 
infants born each year (3).   
 
Birthweight is a function of the duration of gestation and rate of fetal growth, or a combination of 
both (4).  Accordingly, a LBW infant could be result of either an early delivery (PTD) or being born 
small-for-gestational age (SGA), which is commonly used as a measurable proxy for intrauterine 
grown restriction (IUGR) (5).  PTD and SGA are distinct but related outcomes, with different 
etiologies and consequences (short and long term).  In 2010, out of all the 135 million infants born in 
low- and middle-income countries (LMIC) an estimated 43.3 million were born either preterm and/or 
SGA; and the highest prevalence’s were in South Asia and sub-Saharan Africa (SSA) (2).  Infants who 
are preterm-SGA have a 10 to 39 times increased risk of neonatal death compared to otherwise 
normal infants (6, 7).  Even if these infants do survive, they still have to deal with long term 
consequences for child development, educational attainment (8), and quality of life. 
 
Many of the countries where these adverse birth outcomes are common also have the added 
disadvantage of being high HIV prevalence settings.  In particular, the vast majority of infants born to 
HIV-infected women reside in SSA; where the antenatal prevalence exceeds 30% in some areas of 
southern Africa (9).  The management of HIV-infected pregnant women has evolved significantly due 
to advancements in antiretroviral (ARV) drug development and better understanding of mother-to-
child transmission (MTCT).  As ARVs have gotten more efficacious over time, recommended 
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regimens for use during pregnancy have also changed progressively from short course prophylaxis 
for prevention of mother-to-child transmission (PMTCT) to lifelong antiretroviral therapy (ART). 
 
During the last five years, there has been a substantial increase in the number of HIV-infected 
pregnant using ART around the world, and particularly in SSA.  While increased ART access has been 
invaluable for promoting the health of HIV-infected women and their infants, there are ongoing 
concerns surrounding the effects of this in utero ART exposure, with some evidence of increased risk 
of adverse birth (PTD, LBW, and SGA).  Adverse birth outcomes among HIV-infected pregnant women 
on ART were first reported in Europe (10, 11); although this was less clear in Latin and North 
American studies where no associations were observed (12-15).  This raised concern because while 
the majority of this early data came from cohorts in high income countries (10, 16-19); most women 
requiring ART during pregnancy reside in LMIC where neonatal care services are limited, magnifying 
the effects of any increase in adverse birth outcomes.   
 
With more than 1 million pregnancies exposed to ART annually (20), any putative association 
between ART use and birth outcomes has major public health implications.  Additionally, given the 
long term consequences of adverse birth outcomes it is essential to quantify their associations with 




This literature review seeks to appraise published data on adverse birth outcomes associated with 
ART exposure during pregnancy and to identify knowledge gaps and further research needs.   
This review focuses on ART use during pregnancy in SSA, the region with the highest HIV burden; 
however since adverse birth outcomes associated with ART use in pregnancy cut across settings, this 
review will selectively draw on studies from high income countries.  For this review ART will refer to 
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triple drug fixed dose combination, which has been implicated in increased adverse birth outcomes 
compared to prophylaxis. 
 
3. METHODS 
3.1 Search Strategy 
A search of the Medline bibliographic database through the PubMed interface (National Center for 
Biotechnology Information, Bethesda, MD) was performed using the search terms antiretroviral 
therapy, pregnancy outcomes as well as their variations: 
 ART or Antiretroviral Therapy or Triple Drug Antiretroviral or HAART 
AND 
 Pregnant or Pregnancy or Maternal or Maternity 
AND 
 Birth Outcomes or Pregnancy Outcomes  
(Antiretroviral[All Fields] AND ("therapy"[Subheading] OR "therapy"[All Fields] OR 
"therapeutics"[MeSH Terms] OR "therapeutics"[All Fields])) AND (adverse[All Fields] AND ("pregnancy 
outcome"[MeSH Terms] OR ("pregnancy"[All Fields] AND "outcome"[All Fields]) OR "pregnancy 
outcome"[All Fields] OR ("pregnancy"[All Fields] AND "outcomes"[All Fields]) OR "pregnancy 
outcomes"[All Fields])) AND ("0001/01/01"[PDAT] : "2016/12/31"[PDAT]) 
 
The search was restricted to English language publications.  Publications were included in this review 
if the study was conducted in SSA, the population of interest included HIV-infected pregnant women 
on ART during pregnancy and if at least one adverse birth outcome (PTD, LBW, SGA) was an outcome 
of the study.   
 
The titles and abstracts of the publications the search yielded were reviewed, as well as reference 
sections of the studies meeting the inclusion criteria.  Additionally, the reference sections of review 
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articles covering antiretroviral therapy in pregnancy and birth outcomes were reviewed and 
additional publications were identified.  All publications available through 31 December 2016 were 
included in this review.  The included studies are summarized in Tables 1a and 1b.  
 
4. QUALITY AND COMPARABILITY OF STUDIES 
The PubMed search returned 279 publications of which only 10 met the inclusion criteria.  The main 
reasons for exclusion were that the study was conducted outside of SSA, pregnant women were 
treated with <3 antiretroviral drugs without an ART comparator group, and/or study outcomes did 
not include any of the outcomes of interest.  Following the review of the reference sections of the 
included studies and review articles (21-28) an additional 10 studies were identified. 
The included studies were conducted between 2001 (29) and 2014 (30-32); and they represent 16 
countries across SSA.  Countries that had more than one study include South Africa (30, 31, 33-36), 
Botswana (32, 37, 38), Zambia (30, 39), Tanzania (30, 40), Malawi (30, 41) and Cote d’Ivoire (29, 42). 
Tables 2a and 2b summarize the key features reflecting study quality and comparability.  Quality 
criteria were based on study design, sample size and methods of assessing outcomes (primarily 
gestation). 
 
4.1 Study Design 
Sixteen out of the 20 included studies were observational, enabling the researchers to observe 
diverse populations in a range of different settings with the exposure (HIV status or timing of ART 
initiation) determined before the ascertainment of the adverse birth outcomes of interest.  The 
three types of observational studies employed were retrospective and prospective cohort (32, 33, 
36, 37, 39, 41, 43, 44), case-control (45) and cross-sectional (29, 31, 42, 46, 47) studies.  All of the 
retrospective cohort studies (32, 33, 36, 39, 41, 43, 44) identified participants after delivery, 
collected data through data abstraction of routinely recorded clinical information from the antenatal 
and postpartum period.  The two prospective cohorts collected data at various time points at study 
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visits which included questionnaires, anthropometric measurements and sample collection (35, 40).  
The study conducted in Tanzania enrolled women at their first postnatal visit at the designated HIV 
care and treatment centres (40), while the study conducted in South Africa and Zambia enrolled 
women antenatally either at the antenatal clinic or HIV care clinic (35).  A prospective matched case-
control study was conducted in Nigeria with HIV-infected women matched to HIV-uninfected 
controls who were women presenting for antenatal booking who delivered in the hospital (45).  The 
four cross-sectional studies were conducted in Côte d’Ivoire (46, 47), Cameroon (29, 42) and South 
Africa (31).  In these studies, exposures and outcomes were either assessed during one time period 
(29, 47) or were comparative and assessed across several time periods (29, 31, 46).  The studies 
investigating one time period compared women on different ART regimens (efavirenz (EFV)-based vs 
nevirapine (NVP)-based) (42) or women who initiating ART at different time points relative to 
pregnancy (ART initiated before conception vs ART initiated during pregnancy) (47).  The 
comparative cross-sectional studies aimed to determine the association between adverse birth 
outcomes and the different ARV treatment guidelines at the different time points assessed (31, 46).  
In contrast to the observational studies, the four randomized control trials (RCT) (30, 34, 38, 48) by 
nature of their design had highly selected populations with strict inclusion and exclusion criteria.  
The Mma Bana study conducted in Botswana enrolled ART naïve women with CD4 cell count 
≥200cells/µl, randomized to either protease inhibitor (PI)-based or nucleoside reverse transcriptase 
inhibitor (NRTI)-based ART arms between 26 to 34 weeks gestation (38); whereas the PROMOTE-
Pregnant Women and Infants Study in Uganda which also enrolled ART naïve women/ARV-
unexposed women (in last 24 months) had no CD4 cell count restrictions, and randomized women to 
either lopinavir/ritonavir (LPV/r)-based or EFV-based ART arms between 12 to 28 weeks gestation 
(48).  The multicentre studies PROMISE (30) and Kesho Bora (34), both compared single course 
Zidovudine prophylaxis (scZDV) to ART for PMTCT.  The PROMISE study inclusion criteria was ART 
naïve women with CD4 ≥350cells/ µl, randomized to either scZDV, ZDV-based ART or tenofovir (TDF)-
based ART arms at ≥14 weeks gestation.  Kesho Bora study enrolled women with CD4 200-500 
cells/µl, randomized to either scZDV or ART arms. 
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4.2 Sample Size 
The total sample sizes of the included studies ranged from n=188 in a study conducted in Congo (43) 
to n=33 148 in a surveillance study conducted in Botswana (37).  The majority of the studies (12) had 
<1000 participants, 2 studies had >10 000 participants.  
 
4.3 Outcome Assessment 
For the birthweight outcome, birthweight was abstracted from clinical records in all the studies 
which reported their birthweight assessment method (39, 41, 47), one of the studies conducted a 
study measurement of birthweight within 1 week of delivery (41).  Based on the study design 
(retrospective) it can be assumed the other studies also abstracted birthweight from clinical records. 
Across the studies, gestational age (GA) was determined using either last menstrual period (LMP), 
symphysis fundal height (SFH) and/or ultrasound scans (US).  The majority of studies estimated GA 
based on the obstetric records, which was primarily based on LMP and SFH (29, 30, 32, 37, 39, 41, 
43, 44, 47); while the prospective studies measured GA at enrolment using a combination of 
estimation methods (34, 38, 40, 48).  Problems of availability mean ultrasonography is not routinely 
used for GA estimation in LMIC, consequently few of the study populations had US-based GA.  In the 
studies that had US available (32, 34-38, 42-44, 46, 48), this was principally used as part of an 
algorithm for when there was discordancy between measures or unknown LMP.  Four studies did not 
report how they determined their GA (29, 31, 33, 45). 
 
4.4 Summary of Study Quality Appraisal 
 For the purposes of this review, ideally studies of good quality would have adequate sample size, 
designed to avoid selection bias, have high quality measures for outcome assessment, use ART 
regimens widely available in SSA, and have comparison groups of participants who initiated ART 
before conception and those who initiated at different time points during pregnancy.  None of the 
studies fulfilled all these criteria, however Zash et al. (32), Chen et al. (37) and Fowler et al. (30) were 
the closest.   
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5. RESULTS FROM STUDIES REVIEWED 
The results of the review of the included studies will be presented in terms of the exposures (HIV and 
ART status) and the outcomes.  The key findings from the included studies are summarized in Tables 
3a and 3b. 
 
5.1 Outcome Definitions 
Different combinations of adverse birth outcomes were reported by the included studies.  PTD and 
LBW were reported by the majority of studies however SGA was only reported in few studies.  Only 
two studies reported all three outcomes (40, 43). 
 
5.1.1 Preterm Delivery  
Eighteen out of the 20 studies reported PTD as an outcome, with eight of the studies also 
reporting a PTD sub-category(30, 32, 34, 36, 38, 40, 47, 48).  The standard definition of PTD 
promulgated by the WHO and International Federation of Gynaecology and Obstetrics 
(FIGO), is birth at <37 completed weeks (259 days) weeks of gestational age (GA) (49).  WHO 
has also defined sub-categories of PTD based on GA and these are moderate to late PTD (32 
to <37 weeks); very preterm (28 to <32 weeks) and extremely PTD (<28) (50).  The sub-
categories reflect the differences in the survival probabilities and the long term health 
consequences.   
 
The WHO definition of PTD was used in all 18 studies that reported PTD as an outcome; 
however there were differences in the definition of the PTD sub-categories used by the 8 
studies which reported PTD and a PTD sub-category.  The PTD sub-categories were named 
either very PTD, extremely PTD or severely PTD.  Three studies defined the PTD sub-category 
as birth at <34 weeks GA (30, 36, 40), one study defined it as <33 weeks GA (32) while four 
studies defined it as <32 weeks GA (34, 38, 46, 48).    
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5.1.2 Low Birth Weight 
Fifteen out of the 20 studies reported LBW as an outcome, with six studies also reporting a 
LBW sub-category.  The standard WHO definition of LBW is birth weight <2500g, a cut-off 
based on epidemiological observations that these infants are at increased risk of mortality 
compared to normal weight infants; sub-categories of LBW include very LBW (VLBW) defined 
as <1500g and extremely LBW (ELBW) defined as <1000g (51).   
Fourteen studies used the standard WHO definition for LBW, one study defined LBW based 
on birthweight (<2500g) and GA at delivery (≥37) (43).  Five studies used the WHO definition 
for VLBW, while one study defined VLBW as <2000g (29). 
 
5.1.3 Small for Gestational Age 
Only four of the 20 reported SGA as an outcome with one study reporting a SGA sub-
category.  SGA is generally defined as a birth weight < 10th percentile of a reference 
distribution of birth weights specific to gestation age.  The definition of SGA is challenging in 
populations worldwide and no global reference exists because of differences in population 
characteristics which may affect fetal growth patterns and differences in methods used in 
the measurement of gestational age.  Consequently several references exist however there 
are problems associated with them, those based on birthweight tend to be deficient for 
preterm deliveries, unisex references do not account or the known difference in birthweights 
between male and female infants and the individualized references tend to be too 
complicated for use in resource limited settings.  Accordingly difference reference standards 
were used in the studies, of the four studies investigating SGA as an outcome the following 
references standards were used: Botswana norms (32, 37), US standards (40) and Fenton 
Growth Standards (36).  One study did not report which reference standard was used (31). 
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5.2 Associations between ART and Adverse Birth Outcomes 
5.2.1 Adverse Birth Outcomes – pre-ART era data 
In the absence of ART (either for treatment or for PMTCT), maternal HIV infection has been 
associated with adverse birth outcomes (52-57) and increased neonatal mortality.  In these 
early studies, the strongest associations were among women in LMIC and those with lower 
CD4 cell counts.  The proposed mechanisms for these adverse birth outcomes were poor 
maternal health, increased risk factors for coinfections and the acute HIV infection of the 
fetus. 
 
5.2.2 Adverse Birth Outcomes –ART era data 
ART use introduces complexity to interpreting associations with adverse birth outcomes.  
ART may decrease some adverse birth outcomes by improving maternal health and reducing 
acute retroviral infection of the fetus, it would therefore appear to be logical that healthier 
women have better birth outcomes.  However ART may also increase adverse birth 
outcomes through other mechanisms.  This complicates the understanding these competing 
forces and makes the epidemiology of this challenging. 
 
In 2010 WHO treatment guidelines recommended two treatment options based on a CD4 
cell count: Option A (maternal scZDV and infant NVP during pregnancy and breastfeeding) 
and Option B (ART for pregnancy and breastfeeding if >350cells/µl; or lifelong ART if 
≤350cells/µl) (58).  Several studies in high income countries showed increased risk of adverse 
birth outcomes among pregnant women on ART in comparison to those on mono or dual 
therapy (11, 12, 59).  Nine of the included studies evaluated the comparison between scZDV 
and ART, these include observational and randomized studies (29, 30, 32, 34, 37, 39, 40, 44, 
46).   
Between 2009 - 2011, the largest birth surveillance study in Africa (total births n=33 148) 
conducted in Botswana found that, when compared to scZDV, ART (initiated during 
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pregnancy) was found to be associated with an increased rate of PTD (adjusted odds ratio 
(AOR) 1.4, 95% confidence interval (CI) 1.2 - 1.8) and SGA (AOR 1.5, 95% CI 1.2 - 1.9) (37).  
Similarly, findings from a prospective cohort in Tanzania, found that ART (initiated before 
conception), when compared to scZDV, was associated with higher risks of PTD (adjusted 
relative risk (ARR) 1.24, 95% CI 1.05 – 1.47) and VPTD (ARR 1.42, 95% CI 1.02 – 1.91) (40).  In 
this cohort ART (initiated during pregnancy) was also associated with higher risk of severe 
SGA (RR 1.47, 95% CI 1.09 – 1.98).  A comparative cross-sectional study in Cameroon which 
compared outcomes over two time periods found that ART (initiated during pregnancy), 
when compared to scZDV, had an increased risk of LBW (AOR 1.7, 95% CI 1.0 - 2.9) but not 
PTD (AOR 1.9, 95% CI 0.9 - 3.7) (46).  Recent findings from the PROMISE study, appear to 
mirror the observational studies, with ART (initiated in pregnancy) associated with increased 
rate of PTD (25% vs 12%) and LBW (21% vs 13%) compared to scZDV (30).  Data from the 
Kesho Bora study, showed similar rates of PTD in the ART and scZDV arms, while LBW was 
slightly higher in the ART arm (34).   
These results appear to suggest the adverse effect of ART, however in contrast to these 
findings a recent study in Botswana evaluating the current recommended WHO first-line 
regimen (TDF+FTC+EFV) found that ART (initiated during pregnancy), when compared to 
scZDV/other ART had lower odds of any adverse birth outcome (AOR 0.4, 95% CI 0.3 - 0.6) 
and SGA (AOR 0.4, 95% CI 0.2 - 0.7), while there was no difference in PTD (AOR 0.7, 95% CI 
0.5 - 1.1) (32).  The difference in conclusions about the effects of ART use in pregnancy 
between the previous studies and this study could be attributed differences in regimens 
used: these were primarily NVP-based in the previous studies and EFV-based in this study.  
This could suggest that EFV-based regimens have fewer adverse effects than other regimens 
(NVP-based and PI-based) (32). 
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Additionally, the lack of association with adverse birth outcomes when TDF was used with 
EFV, suggests that the PROMISE findings of increased birth outcomes in the ART arms could 
have been a result of drug interactions between TDF and LPV/r.   
In LMIC, ART was previously reserved for women who had advanced disease (low CD4 cell 
count), suggesting that the adverse effects seen in earlier studies could have been subject to 
confounding by indication.  However, studies have shown that even among women receiving 
ART solely for PMTCT (10, 60), suggesting that ART itself could be the problem.   
 
In 2013, WHO guidelines changed to recommend that all HIV-infected pregnant and 
breastfeeding women should initiate ART regardless of clinical or immune status, which 
would be continued for the duration of the MTCT risk period (Option B), with an option for 
continuing lifelong ART (Option B+) (61).  These guidelines were updated in 2015 to 
recommend Option B+ for all pregnant women, which has led to a rapid increase in the 
number of women initiating ART during pregnancy (62), it is therefore important to 
understand the effects of ART in these women.  Three studies evaluated adverse birth 
outcomes among women who initiated ART during pregnancy, and these were either 
comparisons of the effect of different durations of ART (before delivery) or the effect 
different regimens (38, 41, 48).  A retrospective cohort study in Malawi and Mozambique 
comparing ART duration prior to delivery found that there was a significant association 
between PTD and duration of ART with longer duration proving to be protective, this effect 
was however not replicated with LBW(41).  Based on studies conducted in high income 
countries, uncertainties exist regarding the potential adverse effects of PI-based ART 
regimen which suggestions that PI-based regimens could play a significant in increasing the 
risk of adverse birth outcomes.  Two randomized trials Mma Bana (Botswana) and PROMOTE 
(Uganda) investigated the PI effect by comparing PI-based regimens to other non PI-based 
regimens.  In the Mma Bana trial the comparison between PI-based and NRTI-based 
regimens initiated between 26 and 34 weeks gestation, found that the PI arm had higher 
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rates of PTD and that PI regimen was the most significant risk factor for PTD (OR 2.03, 95% CI 
1.26 – 3.27) (38).  These results could help to clarify findings from previous observational 
studies in high income countries that had conflicting results (12, 13, 59) or were 
underpowered to detect differences (63).  However in contrast, another randomized trial 
comparing PI-based (LPV/r) and EFV-based regimens among women initiating between 12 
and 28 weeks gestation, did not find increased risk in the PI arm (OR 1.12, 95% CI 0.63 – 
2.00) (48).  It should however be noted that these two studies had very different gestational 
ages at ART initiation as well as different comparison regimens which could explain the 
different conclusions. 
 
The number of women in LMIC who initiated ART before conception, is relatively low 
however as a result of the recent guideline changes, these numbers will dramatically 
increase due to the growing number of HIV-infected women already on lifelong ART and the 
newly initiating pregnant women who will have subsequent pregnancies.  Few studies have 
evaluated risks associated with ART initiated before conception, and those that have usually 
have small sample sizes, however as the numbers of women in this group rapidly increases it 
will be crucial to monitor potential adverse birth outcomes.  
Following recommendations by WHO for the use of EFV-based regimens, concerns were 
raised regarding congenital abnormalities associated with first trimester EFV exposure.  The 
two studies that evaluated adverse birth outcomes among women ART initiated before 
conception (42, 43), were focused primarily on the effects EFV exposure.  Retrospective 
studies were conducted in Côte d’Ivoire (42) and Congo (43) to compare EFV-based to other 
non EFV-based ART.  The study in Côte d’Ivoire found that there was no significant increased 
risk of PTD and LBW in women on EFV-based ART compared to those on NVP-based ART in 
the first trimester.  In contrast, the study in Congo which compared EFV-based ART to non-
EFV-based ART (primarily but not exclusively NVP-based), found that there was an increased 
risk of LBW but not PTD. 
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Timing of ART initiation with respect to gestation appears to be critical, however there is 
limited data available to allow comparisons of adverse birth outcomes in women on ART 
initiated before conception with outcomes in women on ART initiated during pregnancy.  In 
some studies women on ART initiated before conception were compared to women with 
other regimens during pregnancy, including scZDV; whereas in other studies women on ART 
initiated before conception were combined with women who initiated ART in the first 
trimester use, without accounting for timing of initiation.  Previous studies in high income 
countries demonstrated an increased risk of PTD and/or LBW either in women on ART 
initiated before conception (64, 65) or in women on ART initiated during pregnancy (17, 66).  
Five of the included studies evaluated the comparison of adverse birth outcomes according 
to timing of ART initiation (ART initiated before conception vs ART initiated during 
pregnancy) all of these studies were observational (29, 33, 37, 40, 47). 
 
A South African cohort study which investigated the impact of ART on birth outcomes according 
to timing of ART initiation found that there was no difference in the rate of PTD and LBW 
between women on NNRTI-based ART initiated before conception and those on ART initiated 
after the first trimester (33).  Similarly, findings from cross-sectional studies in Cameroon and 
Côte d’Ivoire also found that when women on ART initiated before conception were compared 
to those who on ART initiated during pregnancy, the rates of adverse birth outcomes (PTD 
and/or LBW) were also comparable (29, 47). 
Results from these studies are however in contrast to findings from larger studies conducted 
in Botswana and Tanzania, which demonstrated increased risk in the women on ART initiated 
before conception when compared to those on ART initiated during pregnancy.  In the 
Botswana birth surveillance study this comparison was only conducted for the SGA outcome, 
since women in both groups had equal chances of experiencing the outcome (37).  In this 
study, women on ART initiated before conception had higher odds of SGA deliveries 
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compared to those who initiated ART before 34 weeks (AOR 1.3, 95% CI 1.0 – 15).  In 
Tanzania the women on ART initiated before conception were at increased risk of PTD (RR 
1.37, 95% CI 1.13 – 1.67) and VPTD (RR 1.65, 95% CI 1.12 – 2.43) but not SGA (40).   
 
5.3 Major methodological concerns in the literature 
Similar to studies conducted in high income countries there are different conclusions reached among 
the studies included in the review, which can be attributed in part to the different methodologies 
used which complicate comparisons of individual studies.  The drivers of the different conclusions 
reached between the studies could be related to the heterogeneous populations studied, varying 
study designs and selection of exposure categories. 
 
5.3.1 Different study populations  
The difficulty in comparing studies from high income countries and those in LMIC is not 
surprising given the stark health and health-care disparities that exist.  However, within SSA 
multiple disparities also exist—across regions, within countries, and between different 
segments of the population.  The regional prevalence is 4.7%, however this varies 
considerably between regions within SSA as well as within individual countries.  Southern 
Africa, which is considered the epicentre of the global epidemic, has the country with the 
highest prevalence (Swaziland) and the country with the largest epidemic (South Africa) (67).  
In contrast, HIV prevalences in East and West Africa are low to moderate ranging from 0.5% 
to 6% (67).  As a result of these differences in the epidemiology of HIV in SSA, differences 
exist between HIV-infected pregnant women populations, in terms of the characteristics of 
the women (demographics, differences in risk of exposure to and transmission of HIV, and 
the prevalence of coinfections); and characteristics of their antenatal and therapeutic 
management.  All these factors complicate study comparisons.  Additionally, over the time 
period that the studies were conducted (2001 – 2014) the profile of HIV-infected women 
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regionally and within countries has changed drastically, as a result of improvements in 
PMTCT programmes. 
 
Similar to HIV-related factors, differences also exist in SSA in terms of background rates of 
adverse birth outcomes.  Women in SSA are exposed to numerous risk factors for adverse 
birth outcomes and these include anaemia, untreated hypertension (68), poor nutritional 
status (69), and other factors related to HIV and low socioeconomic status (SES).  While 
these individual level factors are often considered in studies investigating the association 
between ART and adverse birth outcomes, health system factors which have also been 
shown to influence adverse birth outcomes are not always considered.  Population level 
characteristics, treatment guidelines and polices vary within SSA and this may impact the 
incidence of adverse birth outcomes (35).  This is demonstrated in the study conducted by 
Lui et al, a comparison of two health care systems in Zambia and South Africa, where adverse 
birth outcomes differed significantly between the two cohorts (35).  The authors concluded 
that while differences in maternal characteristics in the two cohorts contributed to the 
differences in rates of adverse birth outcomes, the disparity in the health care systems also 
played a part with fewer adverse birth outcomes in South Africa where women received 
hospital based ANC compared to the primary health care facility based ANC in Zambia (35).   
These individual and population level differences in SSA are likely to contribute to the 
differences in conclusions reached in the various studies conducted in this region and 
internationally. 
 
5.3.2 Different study designs 
The varying study designs used in studies investigating the association between ART and 
adverse birth outcomes could also contribute to different conclusions reached.  In order to 
understand the antecedents and predictors of adverse birth outcomes and any related 
biological mechanisms, investigation of representative populations of HIV-infected 
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pregnant women with high quality measures of study procedures are required.  
Unfortunately this is not always possible, with compromises often having to be made in 
design choices; foregoing strength in some areas for strength in others.  This is 
demonstrated in the studies conducted in Botswana, the two retrospective cohort studies 
were able to evaluate outcomes in approximately 10 000 HIV-infected women (32, 37) 
compared to the RCT which only evaluated outcomes 560 HIV-infected women (38).  
Different study designs provide different data quality because of the compromises are 
made with respect to measurement quality and generalizability of the results.   
Observational studies and RCTs are the main study types used to evaluate the association 
between ART and adverse birth outcomes.  They do not always have same conclusions with 
observational studies tending to overestimate effects and have more variable estimates of 
effects because of residual confounding in comparison to RCTs.  Observational studies 
draw inferences about the effect of the exposure on much wider populations and are often 
population-based.  There may however be large observed and unobserved differences in 
the characteristics of pregnant women in the different treatment groups, leading to biased 
estimates (70).  When information on participant characteristics is missing/unavailable, as 
is common in observational studies, this impacts the ability to adjust for important 
confounders such as demographics, substance use, HIV factors (degree of 
immunosuppression, indication for treatment) and coinfections.  Several of the 
observational studies in this review had these limitations.  The two retrospective cohort 
studies conducted in Botswana (32, 37), had large sample sizes, however because routine 
laboratory tests were inconsistently performed and/or recorded, they had missing CD4 cell 
count and VL data.  Similarly, the retrospective cohort studies in South Africa and 
Cameroon had missing data on coinfections (33, 36), nutritional status (36, 46) and SES 
(33).  Studies conducted in multiple countries or facilities, are also subject to problems of 
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inconsistent data – this was demonstrated in the South African study conducted within 
routine clinical settings had two sites which collected different data (36).   
 
In contrast, this selection bias tends to be absent in RCTs because of the randomization 
which is why these trials are considered to have greater internal validity and provide the 
strongest evidence for concluding causality.  However there are concerns about the 
generalizability of results of these clinical trials, which is influenced by the inclusion and 
exclusion criteria and participant self-selection (71).   
All four RCTs had stringent inclusion and exclusion criteria based primarily on CD4 cell 
count and GA at enrolment.  In the studies that had CD4 cell count inclusion criteria these 
were ≥200 cells/µl for Mma Bana (38); ≥350 cells/µl for PROMISE (30) and between 200-
500cells/µl for Kesho Bora (34).  There were also differences in the GA at enrolment 
criteria, PROMOTE (12-28 weeks), PROMISE (>14 weeks) and Kesho Bora (<32 weeks) 
enrolled women early in pregnancy which enabled evaluation of early events such as VPTD, 
unlike Mma Bana which only enrolled women later in pregnancy (26-36 weeks) 
Because of these inclusion criteria, study populations of RCTs do not tend to mirror the 
population characteristics of the target population (72) and could explain the different 
conclusions reached on observational studies and RCTs. 
 
5.3.3 Measurement of gestation  
Associations of ART and adverse birth outcomes in SSA are greatly affected by the inability to 
obtain precise information on pregnancy duration.  Accurate GA assessment is of critical 
importance for the correct diagnosis of adverse birth outcomes, particularly in these high 
HIV prevalence areas, where ultrasonography is usually unavailable.  It should be noted that 
even when US facilities are available, women in this region tend to seek antenatal services 
later in the pregnancy when biologic variations and effects of growth restriction have 
occurred which affects the precision (73, 74).  Consequently, GA assessment is routinely 
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based on clinical assessment including dating the LMP and measurement of SFH.  However, 
LMP-based GA may be unreliable with recall issues and use of injectable hormonal 
contraception (with lack of, or irregular, periods after cessation), while SFH-based GA 
assessment is affected by poor reproducibility and difficult in women early in pregnancy (<12 
weeks), and in women with high BMI.   
Measurement error in GA assessment may introduce bias where an imprecise GA can result 
in the misclassification of preterm versus term deliveries and preterm versus SGA infants.  
This warrants cautious interpretation of GA at delivery as predicted by either of menstrual 
history or clinical examination, particularly outside the range of term deliveries.   
  
 Since the majority of studies in this review used a combination of LMP and/or SFH for GA 
assessment, misclassification of outcomes is a possibility, which could have substantial 
effects on the inference made from the study findings.  Limiting measurement error in 
epidemiological studies through the use of robust measures with fewer errors will result in 
sounder and more interpretable scientific findings.  These different methods of outcome 
assessments used in the studies are summarized in Tables 2a and 2b. 
 
5.3.4 Different exposure groups 
 The different exposures or comparison groups in studies investigating the associations 
between ART and adverse birth outcomes impacts the comparability of these studies and 
can explain some of the differences in study conclusions.  There were three major groups of 
comparisons in the studies: HIV-infected (on ART) women compared to HIV-infected women; 
HIV-infected women only and HIV-infected women on ART only.  These different exposure 
groups are summarized in Table 4. 
 
 When the exposure groups were HIV-infected (on ART) and HIV-uninfected women, results 
were consistent with higher rates of adverse birth outcomes in HIV-infected women (31, 32, 
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37, 45).  In the comparisons among the ‘HIV-infected women only’ there were many 
different groups of women compared to the women on ART.  These included women who 
were untreated (no ARVs in pregnancy) and women on PMTCT regimens.  In the comparisons 
with untreated women, there were no associations between ART and adverse birth 
outcomes, with higher rates seen in the untreated women (31, 40, 41).   
Among the women on short-course PMTCT regimens, the comparator groups were either 
women on monotherapy only (31, 44) or a combination of women on mono and dual 
therapy (29, 36).  The women on ART were not a homogenous group, in some studies these 
were women who were initiating on ART (30, 37, 40, 46), while it others it was women on 
ART initiated before conception (40). 
 
In the comparisons among the women on ‘ART only’, the women were either compared 
according to timing of initiation or regimen types.  Comparisons of timing of ART initiation 
were between women on ART initiated before conception and those who on ART initiated 
during pregnancy.  Among the women who initiated ART during pregnancy some were either 
restricted i.e. only those who initiated after 1st trimester (33) or categorized as late or early 
(47).  Regimen comparisons among women on ‘ART initiated before conception only’ 
included TDF+3TC+EFV versus any other ART (32), EFV-based versus non EFV-based (43) and 
EFV-based versus NVP-based (42).  Among those on ‘ART initiated during pregnancy’, the 
regimen comparisons were PI-based versus NRTI-based (38), LPV/r-based versus EFV-based 
(48) and ZDV-based versus TDF-based (30). 
 
5.3.5 Different ART regimens 
ART regimens used during pregnancy in SSA consist primarily of reverse transcriptase 
inhibitors, which are drugs with reduced antenatal impairments compared to PI-based 
regimens commonly used in high income countries.  National guidelines on which regimens 
to use during pregnancy have varied across SSA and have changed over time.  Consequently 
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regimens used in studies in SSA are not always widely used within the region.  The studies 
that included details of regimens had the following comparisons: NNRTI-based vs PI-based 
(36, 48); NNRTI-based (TDF+3TC+EFV) vs Other (32, 45), NRTI-based vs PI-based (38),  NNRTI-
based only (29, 31, 39, 42, 43) and PI-based only (30, 34).  This wide range of regimen 
comparisons may also contribute to the different conclusions reached by studies, particularly 
since there is uncertainty about whether any observed associations are drug specific, with 
some but not all reports suggesting that the relationship may be driven in part by PI-based 
regimens (24, 75).  Randomized data from Mma Bana study (38) was similar to observational 
studies that associated PI-based regimens with PTD (36, 60), these results were however 
different from results from the PROMOTE study which found no association between PI-
based regimens and PTD (48).  The PROMISE study results also showed differences by 
regimens, although it was the NRTI backbone (TDF+FTC) that was of concern with 
considerably more severe adverse birth outcomes (VPTD and VLBW) with the TDF+FTC 
backbone compared to the ZDV+3TC backbone (30).  This has raised concerns that TDF+FTC 
backbone when used in combination with LPV/r may contribute to adverse birth outcomes 
particularly since TDF was not associated with adverse birth outcomes when combined with 
EFV in a recent study in Botswana (32).   
WHO currently recommends TDF+FTC+EFV as the first-line regimen – however few studies 
have evaluated adverse birth outcomes associated with this regimen.  Results from a birth 
outcomes surveillance in Botswana, found that there was no increased risk of adverse birth 
outcomes with this regimen regardless of timing of ART initiation (32).    
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6. SUMMARY  
This review shows that in the last five years there has been an increase in larger studies being 
conducted in SSA to examine the associations between ART use and birth outcomes, however the 
current state of epidemiologic knowledge still remains limited because of the limited number of high 
quality prospective studies from the region.  One major factor influencing the study quality in studies 
conducted in SSA is that they rely heavily on LMP and SFH as measures of gestation even though it is 
known that these methods are subject to considerable error.  Additionally, as in studies conducted in 
high income countries, study comparability is limited by the different population characteristics and 
the wide range of exposure groups and ART regimens used.  The majority of the studies reviewed 
were based on regimens not widely used in SSA; and very few studies examined the first-line 
regimen (TDF+3TC+EFV) currently recommended by WHO, which is the most commonly used 
combination of antiretroviral drugs.   
 
7. RECOMMENDATIONS 
Although there is an unquestionable benefit of ART use in pregnancy to both HIV-infected mother 
and her infant, it is clear from the studies included in this review and in studies conducted in other 
settings that there is some link between ART use in pregnancy and adverse birth outcomes.  What 
remains unclear is whether the associations observed between ART and adverse birth outcomes are 
a result of the class of ARV drug used or timing of ART initiation.  One of the problems that exists is 
that in the majority of studies investigating this association, birth outcomes analyses tend to be 
planned or unplanned secondary analyses.  Consequently, data collection procedures are not 
designed to examine this association and so the best high quality measures and procedures are not 
always utilised.  This is predominantly the case with GA assessment and given that adverse birth 
outcomes, notably PTD, are defined by their timing, it is critical that in future studies high quality 
measures of GA assessment are used to ensure an accurate degree of exposure ascertainment.  This 
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will substantially strengthens results and allow inferences into how the timing of ART initiation in 
pregnancy may or may not be associated with adverse birth outcomes. 
 
Another problem that exists is that there is still limited evidence about the risks of fetal exposure to 
different ART regimens.  Recent observational data from Botswana, evaluating adverse birth 
outcomes with in utero exposure to different ART regimens initiated before conception has shown 
that there are differences (in birth outcomes) between regimens (76).  Women on NVP-based and 
LPV/r-based regimens had significantly worse outcomes than those on TDF+FTC+EFV.  This raises the 
question of whether we should be concerned about the continued use of certain older regimens in 
pregnancy.  Regimens used by women initiating ART during pregnancy have changed over time to 
safer regimens, in line with changes in treatment guideline; however women who initiated before 
conception tend to continue using the regimens they were initiated on in the past despite some of 
these regimens being implicated in increasing the risk of adverse birth outcomes.  Further research is 
required on the birth and long term outcomes associated with the use of different regimens in 
pregnancy, which includes the current recommended regimens and any new antiretroviral agents.   
This literature review underscores the need for the examination of representative cohorts that 
provide unique “real world” insights into the potential adverse effects of ART in pregnancy according 
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Ekouevi 2008 Côte d’Ivoire 2001 - 2003 




ART eligible HIV+ pregnant women 358 LBW (<2500g); VLBW (<2000g) 
Olabuji 2010 Nigeria 2007 - 2008 Teaching Hospital ART eligible HIV+ pregnant women 
referred to PMTCT services and delivered 
at hospital 
Matched HIV- women, booked for ANC 




PTD (<37 weeks) 
LBW (<2500g) 
Kesho Bora  2011 Burkina Faso, 
Kenya, South 
Africa 
2005 - 2008 5 Research Sites 
(ANC Clinics) 
HIV+ pregnant women, <32 weeks GA,  
CD4 200-500, WHO clinical stage 1-3 
 
824 PTD (<37 weeks); VPTD (<32 weeks) 




2011 South Africa 2004 - 2007 Integrated ANC-ARV 
Clinics 
(2 Referral Centres) 
HIV+ pregnant women, CD4 <250, 
singleton birth 
1630 PTD (<37 weeks); EPTD (<34 weeks) 
LBW (<2500g); VLBW (<1500g) 
SGA (<10
th
 percentile – Fenton Standard) 
 
Powis 2011 Botswana 2006 - 2008 4 Research Sites ART naïve HIV+ pregnant women 
CD4 ≥200, 26 -34 weeks GA 
 
560 PTD (<37 weeks); VPTD (<32 weeks) 
Marazzi 2011 Mozambique, 
Malawi 
2005 - 2009 Project ANC Centres Birth outcome data available, intends to 
follow-up at study centres pp 
 
3273 PTD (<37 weeks) 
LBW (<2500g) 
Ekouevi 2011 Côte d’Ivoire 2003 - 2009 4 HIV Care Centres HIV+ pregnant women preconception ART 
(EFV-based or NVP-based) 
 
344 PTD (<37 weeks) 
LBW (<2500g) 
Chen 2012 Botswana 2009 - 2011 6 Government 
Hospitals 
HIV+ and HIV- pregnant women, delivered 




PTD (<37 weeks) 
SGA (<10
th
 percentile - Botswana Norms) 
Anji 2013 South Africa 2008 - 2009 Large Academic 
Hospital 
HIV+ pregnant women, booked ANC and 
delivered at study hospital 
 
245 PTD (<37 weeks) 
LBW (<2500g) 
Kebede  2013 Ethiopia 2009 - 2012 2 District Hospitals 
1 Referral Hospital 
All infants born to HIV+ women  416 PTD (<37 weeks) 
LBW (<2500g) 
 
*total population includes both HIV-infected (HIV+) and HIV-uninfected women (HIV-) 
Preconception ART – ART initiated before conception; Initiating ART – initiated ART during pregnancy, PHC – primary health care, pp – postpartum, HEU – HIV exposed uninfected infant, VPTD – very PTD, EPTD – extremely, 
VLBW – very LBW, SSGA – severe SGA, mod SGA – moderate to severe SGA  
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Koss 2014 Uganda 2009 - 2012 District Hospital ART naïve (or no ARV in 24mo) HIV+ 
pregnant women, 12-28 weeks GA 
389 PTD (<37 weeks); VPTD (<32 weeks) 
Composite (PTD, SB and Miscarriage) 
Nlend 2014 Cameroon 2008 - 2013 ARV Treatment 
Referral Centre 
ART exposed HIV+ women with live births 617 PTD (<37 weeks); SPTD (<32 weeks) 
LBW (<2500g) 
Lui 2014 South Africa, 
Zambia 
2010 - 2011 SA: 1 Referral Hospital 
Zambia: 5 PHC Clinics 
Preconception ART HIV+ pregnant women 600 PTD (<37 weeks) 
Li 2015 Tanzania 2004 - 2011 10 HIV Care and 
Treatment Centres 
Postpartum HIV+ women with HEU infant 3314 PTD (<37 weeks); VPTD (<34 weeks) 
LBW (<2500g); VLBW (<1500g) 
SGA (<10
th
 percentile - US standards) 
SSGA (<3
rd
 percentile - US standards) 
Bisio 2015 Congo 2005 - 2012 Research Sites 
(ANC Clinics) 
All women enrolled in PMTCT projects 
over2 time periods 2005-2008; 2009-2012 
188 PTD (<37 weeks)  
LBW (≥37 weeks GA and BW <2500) 
Bengtson 2016 Zambia 2009 - 2013 ANC Clinics HIV+ women, Initiating ART CD4 ≤350 
(restricted to singleton births >37 weeks) 
4474 LBW (<2500g) 





2011 - 2014 Research Sites ART naïve HIV+ pregnant women, CD4 
≥350 (or country specific threshold),  
≥14 weeks GA  
3490 PTD (<37 weeks); VPTD (<34 weeks) 
LBW (<2500g); VLBW (<1500g) 
Zash 2016 Botswana 2009 - 2011 
2013 - 2014 
2 Maternity Hospitals HIV+ and HIV- pregnant women, delivered 
live-born or stillborn infants  
31463* 
(9445) 
PTD (<37 weeks); VPTD (<33 weeks) 
SGA (<10
th
 percentile - Botswana Norms) 
Any ABO (any SB, PTD or SGA) 
Moodley 2016 South Africa 2011 
2014 
Regional Hospital HIV+ and HIV- women with birth 
outcomes recorded, delivering a neonate 
>500g
9847 PTD (<37 weeks); mod PTD (<34 week) 
LBW (<2500g); VLBW (<1500g) 
SGA (definition NR) 
Nlend 2016 Cameroon 2008 - 2011 PMTCT Programme 
(Referral Hospital) 
HIV+ women, initiating ART, singleton 
birth 
760 PTD (<37 weeks) 
LBW (<2500g) 
*total population includes both HIV-infected (HIV+) and HIV-uninfected women (HIV-) 
Preconception ART – ART initiated before conception, Initiating ART – initiated ART during pregnancy, PHC – primary health care, pp – postpartum, HEU – HIV exposed uninfected infant, VPTD – very PTD, EPTD – extremely PTD, 
VLBW – very LBW, SSGA – severe SGA, mod SGA – moderate to severe SGA
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Table 2a.   Key features of quality of included studies (2008-2013) 
 
Study Study Design Data Collection Comparison Groups Regimen/Exposure Outcomes Assessment 
Ekouevi Repeated Cross-sectional NR  PMTCT group vs ART group 
 PMTCT group: Monotherapy vs Dual Therapy 
 ART group: Preconception vs Initiating 
 
 ART group: 87% ZDV+3TC+NVP 
 PMTCT group: 54% scZDV; %NR sc(ZDV+3TC) 
NR 
Olabuji Matched Case-Control NR  HIV+ (on ART) vs HIV- 
 
 NR NR 
Kesho 
Bora  
RCT Study Measures 
(visits every 2 weeks until 
delivery) 
 ART Group vs Monotherapy Group  ART group: ZDV+3TC+LPV/r 
 Monotherapy group: scZDV  
 







Data Abstraction  ART unexposed (no antenatal ARVs) 
 ART exposed: Initiated <28 weeks (early) vs 
Initiated ≥28 weeks (late) 
 Clinic 1: d4T +3TC+ LPV/r 
 Clinic 2: d4T+3TC+ NVP 
 Preconception ART regimen continued; EFV-based 
switched to PI-based if <1
st
 trimester  
 
US (when available), LMP 
and SFH  
(Obstetric Record) 
 
Powis RCT  
(Retrospective Analysis) 
Study Measures  Initiated ART (regimens compared)  51% ABC+ZDV+3TC; 49% ZDV+3TC+LPV/r LMP and US  
(Study Clinicians) 
Marazzi Retrospective  
Observational Cohort 
Data Abstraction  ART duration  
(None vs 0-30days vs 31-90days vs >90days) 
 Lifelong ART: d4T-based/ZDV based 
 Stopped 6mo pp: d4T-based/ZDV based 
SFH and LMP (Obstetric 
Record) 
 
Ekouevi Retrospective  
Observational Cohort 
Data Abstraction  Preconception ART: EFV-based vs NVP-based 2 drugs associated with EFV or NVP: 
 60% ZDV+3TC; 37% d4T+3TC; 2% TDF+FTC;  
1% DDI+d4T 
 




Data Abstraction   HIV + vs HIV- 
 Preconception ART vs ALL other HIV+  
 Initiated ART vs scZDV (≤34 weeks)  
 Preconception ART vs Initiated ART   
 
 87% ZDV+3TC+NVP; 9% ZDV+3TC+LPV/r; 
4% Other (NR) 
LMP - if 
unknown/discordant with 
SFH, US used (Obstetric 
Record) 
Anji Retrospective  
Observational Cohort 
Data Abstraction  Preconception ART  
 Initiated ART (<1st trimester) 
 Preconception: 96% NNRTI-based; 4% PI-based 
 Initiated: 95% NNRTI-based; 5% PI based 
 
NR 
Kebede  Retrospective  
Observational Cohort 
Data Abstraction  
(Delivery Record and PMTCT 
Record) 
 No ARVs 
 PMTCT Group 
 ART Group 
 
 NR LMP, SFH and US (when 
available)  
(Obstetric Record) 
Koss RCT (Secondary Analysis) Study Measures  Initiated ART: LPV/r based vs EFV-based  50% ZDV+3TC+LPV/r; 50% ZDV+3TC+EFV LMP GA used if concordant 
with US GA. US used if LMP 
and US discordant (Study 
Staff) 
Study Measures – study visits with questionnaires, anthropometric measurements and specimen collection 
Preconception ART – ART initiated before conception, Initiating ART – initiated ART during pregnancy, ART group - >3 antiretroviral drugs, PMTCT - <3 antiretroviral drugs, pp – postpartum, NR - not reported  
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Table 2b.   Key features of quality of included studies (2014-2016) 
 
Study Study Design Data Collection Comparison Groups Regimen/Exposure Outcomes Assessment 
Nlend Nested Cross-sectional  Data Abstraction (PMTCT 
Registers) 
 Preconception ART vs Initiated ART 
 Initiated ART: <28 weeks (early) vs ≥28 weeks 
(late) 
 Preconception group: 68% ZDV+3TC+NVP; 14% 
ZDV+3TC+EFV; 10% TDF+3TC+NVP; 4% 
TDF+3TC+EFV; 4% PI-based 
 Initiated group: 64% ZDV+3TC+NVP; 26% 
ZDV+3TC+EFV; 4% TDF+3TC+NVP; 4% PI-based 
 
LMP (Obstetric Record) 
Lui Prospective Cohort Study Measures and Data 
Abstraction 
 South African women (high risk) 
 Zambian women (low risk) 
 d4T+3TC+NVP (56% SA; 30% Zam); TDF-based 
(25% SA; 44% Zam); EFV-based (53% SA; 26% 
Zam); PI-based (8% SA; 2% Zam) 
 
LMP (Zambia); US (South 
Africa) 
Li Prospective Observational 
Cohort 
Study Measures  ZDV vs Preconception ART 
 ZDV vs Initiated ART 
 ZDV vs Preconception ART vs Initiated ART 
 
 80% ZDV+3TC+NVP; 11% d4T+3TC+NVP; 3% 
ZDV+3TC+EFV; 6% Other (NR) 
LMP and SFH (Study 
Clinician) 
Bisio Retrospective  
Observational Cohort 
Data Abstraction  Preconception ART: EFV-based vs non-EFV 
based 
 81% non EFV-based (ZDV+3TC+NVP and 
d4T+3TC+NVP); 19% EFV-based (ZDV+3TC+EFV 
and d4T+3TC+EFV) 
 
LMP and US (when 
available) (Obstetric 
Record) 
Bengtson Retrospective  
Observational Cohort 
Data Abstraction  
(Zambia Electronic Perinatal 
Record System and Maternity 
Registers) 
 Duration of ART (Initiated): Never Initiated vs 
≤8 weeks vs 9-20 weeks vs 21-36 weeks 
 Regimen data not available (recommended 1st 
line NNRTI-based 
 Never Initiated: ZDV (with or without sdNVP) 
 
<20 weeks: LMP 
>20 weeks: both LMP and 
SFH 
Fowler Open label RCT Study Measures 
(antenatal visits 2, 4, 8, 12 weeks 
and then every 4 weeks till 
delivery) 
 Initiated scZDV vs ZDV-based ART vs TDF-
based ART 
 ZDV-based ART vs TDF-based ART 
 ZDV + sdNVP + (TDF+FTC) 
 ZDV +3TC + LPV/r 
 TDF + FTC + LPV/r 
 
Ballard Score or Obstetric 
Estimate (Obstetric Record) 
Zash Retrospective  
Observational Cohort 
Data Abstraction  Initiated: TDF+3TC+EFV vs scZDV vs Other ART 
 Initiated: TDF+3TC+EFV vs Other ART 
 Preconception: TDF+3TC+EFV vs Other ART 
 
 ARVs initiated: ZDV+3TC+NVP; ZDV+3TC+LPV/r; 
TDF+FTC+NVP 
 
LMP, SFH and US 
(occasionally used if LMP 
unknown) 
Moodley Cross-sectional Data Abstraction  HIV+ vs HIV- 
 No ARV vs Monotherapy vs ART 
 ZDV + sdNVP 





Data Abstraction (PMTCT 
Registers) 
 ART group 
 Monotherapy group 




Study Measures – study visits with questionnaires, anthropometric measurements and specimen collection 
Preconception ART – ART initiated before conception, Initiating ART – initiated ART during pregnancy, ART group - >3 antiretroviral drugs, PMTCT - <3 antiretroviral drugs, pp – postpartum, NR - not reported  
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Ekouevi  ART (vs scZDV/ZDV+3TC) had a higher proportion of LBW (22% vs 12%). This did not vary by PMTCT subgroup or by timing of ART initiation 
 ART (vs scZDV/ZDV+3TC) had similar rates of VLBW 
 Preconception ART (vs Initiated ART) had similar rates of LBW (20.5% vs 21.5%) and VLBW 
 
Olabuji  HIV+ on ART (vs HIV-) had increased risk of PTD (OR 2.89, 95% CI 1.2 – 7.0) and LBW (OR 5.43, 95% CI 2.4 – 12.0)  
 
Kesho Bora   ART (vs scZDV) no difference in prevalence of PTD (13% vs 11%) 
 ART (vs scZDV) slight difference in prevalence of LBW (11% vs 7%) 
 
Van der Merwe  ART-unexposed (vs early ART-exposed vs late ART-exposed) (27% vs 23% vs 19%)  
 ART exposure (vs ART-unexposed) had increased risk of PTD (15% vs 5%) 
 Early NVP-based and EFV-based (vs ART-unexposed) had increased risk of PTD (AOR 5.4, 95% CI 2.1 - 13.7 and AOR 5.6, 95% CI 2.1 - 15.2 respectively) 
 
Powis  PI group (ZDV+3TC+LPV/r) (vs NRTI group (ABC+ZDV+3TC)) rates of PTD (21.4% vs 11.8%) 
 PI group (ZDV+3TC+LPV/r) (vs NRTI group (ABC+ZDV+3TC)) increased risk of PTD (OR 2.03, 95% 1.26 - 3.27) 
 
Marazzi  At least 90days ART (vs No ART) was protective of PTD (OR 0.15, 95% CI 0.14 – 0.19) 
 LBW not associated with ART duration 
 
Ekouevi  EFV-based ART (vs NVP-based ART) had no increased risk of PTD (9.5% vs 12.7%) 
 EFV-based ART (vs NVP-based ART) had no increased risk of LBW (17.2% vs 24.2%) 
 EFV-based ART (vs NVP-based ART) similar proportion of miscarriages and stillbirths 
 
Chen  Maternal HIV was significantly associated with PTD and SGA 
 Preconception ART (vs other HIV+ women) had higher odds of PTD (AOR 1.2, 95% CI 1.1 - 1.4) and SGA (AOR 1.8, 95% CI 1.6 - 2.1) 
 ART initiated during pregnancy (vs scZDV) had higher odds of PTD (AOR 1.4, 95% CI 1.2 - 1.8) and SGA (AOR 1.5, 95% CI, 1.2 - 1.9) 
 Preconception ART (vs Initiated ART <34v, no events before 34wks) had higher odds of SGA (AOR 1.3, 95% CI 1.0 - 15) 
 
Anji  Preconception ART (vs Initiated ART) PTD rates did not differ significantly (21% vs 24%) 
 Preconception ART (vs Initiated ART) LBW rates did not differ significantly (21% vs 24%) 
 
Kebede   ARV exposed (ART and scZDV) (vs untreated) had lower risk of PTD (12% vs 24%) 
 ART initiated during pregnancy (vs preconception ART) increased risk of PTD (AOR 1.82, 95% 1.02 - 3.81) 
 ART exposed (vs ART-unexposed) had higher prevalence of LBW (39% vs 6%) 
 ART exposed (vs ART-unexposed) increased risk of LBW (AOR 8.24, 95% CI 2.53 - 14.34) 
 
Koss  LPV/r-based ART (vs EFV-based ART) had similar rates of PTD (14.7% vs 16.2%) 
 LPV/r-based ART (vs EFV-based ART) had no increased risk of PTD (OR 1.12, 95% CI 0.63 – 2.0) 
 
Preconception ART – ART initiated before conception, Initiating ART – initiated ART during pregnancy 
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Key Finding  
 
Nlend  Preconception ART (vs Initiated ART) similar rates of PTD (8.1% vs 10.1%) 
 Among initiated ART: early ART (vs late ART) had similar rates of PTD (10.9% vs 9%) 
 Preconception ART (vs Initiated ART) similar rates of LBW (11.7% vs 11.6%) 
 Among initiated ART: early ART (vs late ART) had higher odds of LBW (AOR 1.87, 95% CI 1.02 - 3.44) 
 
Lui  Zambian women (vs South African women) had higher rates of PTD (29.7% vs 18.4%) 
 Zambian women (vs South African women) had higher rates of LBW (18.1% vs 15.5%) 
 
Li  Preconception ART (vs  ZDV) higher risks of PTD (ARR 1.24, 95% CI 1.05 – 1.47) and VPTD (ARR 1.42, 95% CI 1.02 – 1.919) 
 ART initiated during pregnancy (vs ZDV) associated with higher risk of SSGA (RR 1.47, 95% CI 1.09 – 1.98) 
 ART initiated during pregnancy (RR 1.31, 95% CI 1.04 – 1.65) and preconception ART (RR 1.34, 95% CI 1.05 – 1.71) (vs ZDV) higher risk of LBW 
 Preconception ART (vs ART initiated during pregnancy) associated with higher risks of PTD (RR 1.37, 95% CI 1.13 – 1.67) and VPTD (RR 1.65, 95% CI 1.12 – 2.43) but not 
SGA 
 
Bisio  EFV-based ART (vs non EFV-based ART) had no increased risk of PTD (13% vs 10%) 
 EFV-based ART (vs non EFV-based ART) had increased risk of LBW in term deliveries (33% vs 16%) 
 EFV-based ART (vs non EFV-based ART) had increased risk of composite adverse birth outcomes (49% vs 28%) 
 
Bengtson  Initiated ART (different durations) (vs never initiated (ZDV (with or without sdNVP)/sdNVP/unknown)) no increased risk of LBW among term infants. 
 Initiated ART 1-8 weeks (vs never initiated) (RR 1.22, 95% CI 0.77 - 0.91) 
 Initiated ART 9-20 weeks (vs never initiated) (RR 1.23, 95% CI 0.82 - 1.83) 
 Initiated ART 21-36 weeks (vs never initiated) (RR 0.87, 95% CI 0.22 - 3.46) 
 
Fowler  Both ART arms (vs scZDV) had higher prevalence of composite adverse birth outcomes: ZDV-based ART (40% vs 28%) and TDF-based ART (35% vs 27%) 
 ZDV-based ART (vs scZDV) had higher prevalence of PTD (20.5% vs 13.1%) and TDF-based ART had higher prevalence of VPTD (6.0% vs 2.6%) 
 Both ART arms (vs scZDV) had higher prevalence of LBW: ZDV-based ART (23.0% vs 12.0%) and TDF-based ART (16.9% vs 8.9%) 
 ZDV-based ART (vs TDF-based ART) no differences in adverse events 
 
Zash  Initiated ART (TDF+FTC+EFV) (vs ZDV/other ART) had decreased risk of any adverse birth outcome (AOR 0.4, 95% CI 0.3 - 0.6) 
 Initiated ART (TDF+FTC+EFV) (vs ZDV/other ART ) had decreased odds of SGA infants (AOR 0.4, 95% CI 0.2 - 0.7) and no increased risk of PTD (AOR 0.7, 95% CI 0.5 - 1.1) 
 Preconception ART (TDF+FTC+EFV) (vs Other ART) reduced overall adverse birth outcomes (33% vs 51%) and SGA (8% vs 24%) 
 
Moodley  HIV+ on ART (vs HIV-) had increased risk of PTD (AOR 1.26, 95% CI 1.14 - 1.4), LBW (AOR 1.26, 95% CI 1.11 - 1.43) and SGA (AOR 1.15, 95% CI 0.98 - 1.35) 
 ART (TDF+FTC+EFV) (vs no ARVs) had decreased risk of PTD (OR 0.31, 95% CI 0.11 - 0.9) and LBW (OR 0.12, 95% CI 0.04 - 0.37) 
 
Nlend  Initiated ART (vs ZDV) had no increased risk of PTD (AOR 1.9, 95% CI 0.9 - 3.7) 
 Initiated ART (vs ZDV) had increased risk of LBW (AOR 1.7, 95% CI 1.0 - 2.9) 
 
Preconception ART – ART initiated before conception; Initiating ART – initiated ART during pregnancy 
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Studies of antiretroviral therapy (ART) use during pregnancy in HIV-infected women have 
suggested that ART exposure may be associated with adverse birth outcomes.  However 
there are few data from sub-Saharan Africa where HIV is most common, and few studies 
involving the World Health Organization’s (WHO) recommended first-line regimens.  
Methods 
We enrolled consecutive HIV-infected pregnant women and a comparator cohort of 
uninfected women at a primary-level antenatal care facility in Cape Town, South Africa.  
Gestational assessment combined clinical history, examination and ultrasonography; 
outcomes included preterm (PTD), low birthweight (LBW) and small for gestational age (SGA) 
deliveries.  In analysis we compared birth outcomes between HIV-infected and -uninfected 
women, and HIV-infected women who initiated ART before versus during pregnancy.  
Results 
In 1554 women (mean age 29 years) with live singleton births at time of analysis, 82% were 
HIV-infected, 92% of received first-line regimen of tenofovir, emtricitabine and efavirenz.  
Overall, higher levels of PTD (22% vs 13%; odds ratio (OR) 1.94, 95% CI: 1.34, 2.82) and LBW 
(14% vs 9%; OR 1.62, 95% CI: 1.05, 2.29) were observed in HIV-infected versus uninfected 
women although SGA deliveries were similar (9% vs 11%; OR 1.06, 95% CI: 0.71, 1.61.  
Adjusting for demographic characteristics and HIV disease measures, HIV-infected (versus 
HIV-uninfected) women had persistently increased odds of PTD [adjusted odds ratio (AOR) 
2.03; CI 1.33, 3.10]; associations with LBW were reduced (AOR 1.47; CI 0.90, 2.40).  Among 
all HIV-infected women, there appeared to be no association between the timing of ART 
initiation (before or during pregnancy) and adverse birth outcomes. 
Conclusions 
These findings suggest that current WHO-recommended ART regimens appear relatively safe 
in pregnancy, although more data are required to understand the aetiology of preterm 
delivery in HIV-infected women using ART. 
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1. BACKGROUND
Use of triple-drug antiretroviral therapy (ART) during pregnancy is the central intervention to 
promote the health of HIV-infected women and their children.  Widespread ART access has 
significantly reduced the number of new pediatric HIV infections and improved the long-term 
health of HIV-infected mothers, representing one of the greatest successes of the public 
health response to the HIV epidemic (1). 
However there are persistent questions regarding the potential effects of in utero ART 
exposure.  While the association between untreated, advanced HIV disease and adverse birth 
outcomes is well documented (2, 3), a number of studies have suggested increased levels of 
preterm delivery (PTD) (4-7), low birthweight (LBW) (8-10), and/or small for gestational age 
(SGA) (4, 11) deliveries among women receiving ART.  Findings vary by the class of 
antiretroviral agents (ARVs) used with protease inhibitors (PIs) more commonly implicated 
than nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs 
respectively) (12-15).  However, overall findings for the putative association between 
antenatal ART use and adverse birth outcomes are highly mixed, with many studies finding no 
evidence of associations with PTD, LBW and/or SGA (11, 16-21).   
With approximately 1.4 million HIV-infected women becoming pregnant annually (22), the 
possibility of an increased risk of adverse birth outcomes has generated considerable concern. 
The current evidence base is subject to several notable limitations.  Few studies have focused 
on African populations where most pregnant women using ART live and where rates of PTD 
are often high (23, 24).  In addition most studies investigate ARVs not widely used in low- and 
middle- income countries (LMIC), and there are few data examining the World Health 
Organization (WHO) recommended regimen of two NRTIs [tenofovir (TDF) and emtricitabine 
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(FTC)], with the NNRTI efavirenz (EFV).  And while accurate pregnancy dating is critical for 
defining adverse outcomes in perinatal epidemiology, the quality of gestational dating in the 
existing literature is variable, and subsequent potential for bias poorly understood.  Finally, 
the choice of comparison groups varies between studies, and in studies without HIV-negative 
or HIV-infected, ART-unexposed comparator groups it can be difficult to attribute adverse 
effects to ART exposure rather than HIV disease (8).  
Given the large numbers of ART-exposed pregnancies around the world and the conflicting 
evidence to date, better understandings of the potential associations between commonly 
used ART regimens, and adverse birth outcomes are critical (25).  In particular, with national 
treatment programmes in high-burden countries implementing a first-line regimen of 
TDF+FTC+EFV for all HIV-infected women regardless of disease status or CD4 cell count, data 
on how this regimen may affect major birth outcomes are urgently required.  Therefore, we 
examined the associations between ART use and birth outcomes in a well-characterised 
cohort of women seeking routine public sector antenatal care Cape Town, South Africa.  
2. METHODS
Study Setting 
This prospective cohort study was conducted among consecutive HIV-infected and HIV-
uninfected women seeking antenatal care (ANC) at a large, community-based public sector 
primary care facility in Cape Town, South Africa enrolled between April 2013 and August 
2015.  The facility serves a catchment population of approximately 350,000 where ANC 
uptake is high (95%); in 2014 the antenatal HIV seroprevalence was estimated at 30% (26).  
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All women in this setting have gestational age estimated based on last menstrual period 
(LMP) and symphysis-fundal height (SFH) at the first ANC visit as part of routine clinical care at 
their first ANC visit.  
 
All women without a previous HIV diagnosis underwent HIV testing, with ART eligibility based 
on CD4 cell count <350 cells/µl or WHO stage III/IV disease (from April to June 2013) or 
universal ART eligibility, regardless of CD4 cell count or disease stage (July 2013 onwards).  
HIV-infected women conceiving while on ART continued their current regimen throughout 
pregnancy; regimens included PIs (used in this setting predominantly after failure of first-line 
therapy) or NNRTIs such as EFV or nevirapine (NVP, used in previous first-line regimens).  For 
women initiating ART in pregnancy, a fixed-dose combination of TDF+FTC+EFV was used 
throughout.  Following ART initiation, clinical follow-up was through an integrated primary 
care service providing antenatal and HIV care.   
 
 2.1 Study Procedures 
This analysis draws on data from a larger multicomponent study of antiretroviral 
services for HIV-infected women during pregnancy and postpartum 
(https://clinicaltrials.gov/ct2/show/NCT01933477) (27).  HIV-uninfected women were 
enrolled consecutively into a separate comparator cohort with identical study 
procedures.  The parent study was reviewed and approved by the University of Cape 
Town Faculty of Health Sciences Human Research Ethics Committee and Columbia 
University Medical Center Institutional Review Board.  Written informed consent was 
obtained from all participants at their first ANC visit and this consent included access to 




Inclusion and Exclusion Criteria 
Consecutive women (≥18 years) attending their first antenatal care visit, who were 
identified as HIV-infected through routine rapid antibody tests were eligible for 
enrolment into the HIV-infected cohort.  Women not eligible for ART at their first ANC 
visit (receiving ZDV prophylaxis) were excluded from this analysis.  For the comparator 
HIV-uninfected cohort, women were eligible for enrolment based on the same criteria 
provided a negative test on the same routine rapid antibody test.   
Data Collection 
All women (HIV-infected and HIV-uninfected) completed questionnaires including 
demographics, obstetric and medical history.  HIV-infected women provided 5mL of 
blood for viral load (VL) testing using Abbot Realtime HIV-1 assay (Abbot Laboratories, 
Waltham, MA).  At their first visit, an obstetric ultrasound (US) was performed on all 
women by an experienced research sonographer using a standardised assessment 
protocol and blinded to other clinical details.  Follow-up study interviews, separate from 
routine clinical care, were scheduled around the second ANC visit,  late 3rd trimester and 
within 7 days postpartum.  Obstetric outcomes, including date and mode of delivery and 
birthweight, were abstracted from obstetric records at delivery facilities.   
2.2 Data Analysis 
In analysis, gestation was based on completed weeks using the best available measure 
(US or combination of LMP/SFH at later gestations).  HIV/ART status (the exposure of 
interest) was categorized as (i) HIV-uninfected; (ii) ART initiated before pregnancy; and 
ART initiated during pregnancy in the (iii) first trimester (<14 weeks), (iv) first half of the 
second trimester (14-20 weeks), (v) second half of the second trimester (21-27 weeks) 
or (vi) third trimester (≥28 weeks).  Regimens were categorized as either PI or NNRTI; 
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NNRTI regimens were either EFV-based (TDF+3TC+EFV), NVP-based (TDF+3TC+NVP) or 
involving other NNRTIs.   
 
All deliveries before September 2015 were included in analysis.  PTD was defined as 
delivery at <37 weeks’ gestation, categorized as late preterm (34–37 weeks), moderately 
preterm (32-34 weeks) or very preterm (<32weeks).  LBW was defined as birthweight 
<2500g and very low birth weight (VLBW) as <1500g.  Using the INTERGROWTH-21st 
Project Standards, infants with birthweights <10th percentile for gestational age were 
classified SGA; those between 10th - 90th percentile were classified appropriate for 
gestational age (AGA); and >90th percentile were classified large for gestational age 
(LGA) (28, 29).  Composite pregnancy loss was defined as any loss before delivery, and 
included ectopic pregnancies as determined by the research sonographer; miscarriages 
defined as pregnancy loss <28 weeks (30); and stillbirths defined as fetal death occurring 
before/during labour and delivery (based on a 1-minute APGAR score of 0).  
 
Statistical analyses (STATA 14.0, Stata Corporation, College Station, TX, USA) focused on 
three exposure comparisons: HIV-infected versus HIV-uninfected women (Comparison 
A); among HIV-infected women, those initiating ART before pregnancy versus those 
initiating during pregnancy (Comparison B); and among women initiating ART during 
pregnancy, comparisons across gestational ages at ART initiation (Comparison C).  
Pregnancy outcome analyses were restricted to live singleton births.  In bivariable 
analyses, proportions were compared using chi-squared and rank-sum tests.  Birth 
outcomes (PTD, LBW and SGA) were compared using unadjusted and adjusted logistic 
regression; results are presented as odds ratios (OR) with 95% confidence intervals (CI).  
Confounders identified a priori included age, maternal height, parity and previous PTD; 
and among HIV-infected women, pre-ART CD4 count and pre-ART VL.  Subgroup 
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analyses involved restrictions by EFV or PI use, and by gestation at first ANC visit.  Model 
fit was assessed using likelihood ratio tests and Akaike’s Information Criterion; 
throughout, statistical tests were 2-sided (alpha=0.05).   
3. RESULTS
A total of 1793 women who had delivered at the time of analysis were included: 1494 (83%) 
HIV-infected and 299 (17%) HIV-uninfected.  Among  HIV-infected women, 572 (38%) initiated 
ART before the current pregnancy and 922 (62%) initiated during pregnancy: 186 during the 
first trimester, 289 during the first half and 256 during the second half of the second 
trimester, and 191 during the third trimester (Figure 1).  TDF+FTC+EFV was the most 
commonly used regimen and 6% reported PI use. 
Table 1 compares demographic and clinical characteristics of women at their first ANC visit.  
Compared to HIV-uninfected women, women who were HIV-infected were older, less 
educated, more likely to be unemployed and more likely to have previous adverse birth 
outcomes, but gestation at first ANC visit did not vary systematically between these groups. 
Among HIV-infected women, those initiating ART before pregnancy were older and less 
educated than women initiating during pregnancy.  Neither pre-ART CD4 cell count nor pre-
ART HIV VL appeared associated with timing of ART initiation in pregnancy among women 
newly initiating ART. 
Figure 1 shows the cohort disposition through delivery.  Overall 121 pregnancies (7%) were 
missing outcome data, principally among those on ART before pregnancy.  Following exclusion 
of 40 twin deliveries and 77 pregnancy losses (4%), 1554 live singleton births were available 
for analysis.  No difference was observed in the composite pregnancy loss outcome by HIV 
status or timing of ART initiation.  HIV-uninfected women experienced a higher proportion of 
64 
 
miscarriages (n=13; 4%) compared to their HIV-infected counterparts (n=25; 2%); while the 
opposite was observed with stillbirths with HIV-infected women experiencing a higher 
proportion (n=34; 2%) compared to HIV-uninfected women (n=1; 0.3%) (Figure 1). 
 
 3.1 Birth outcomes by HIV/ART status 
Comparing outcomes overall between HIV-infected (n=1276) and uninfected (n=278) 
women (Comparison A), a higher incidence of any PTD (OR 1.94, 95% CI: 1.34, 2.82; 22% 
vs 13%) and any LBW (OR 1.62, 95% CI: 1.05, 2.29; 14% vs 9%) was observed among the 
HIV-infected women.  SGA deliveries were similar (OR 1.06, 95% CI: 0.71, 1.61; 9% vs 
11%) (Figure 2).  In both groups, most preterm deliveries were either late (59% and 58%) 
or moderately preterm (32% and 36%); similarly, most newborns were LBW (87% and 
88%) rather than VLBW (Table 2).  Following adjustment for age, parity, height and 
previous PTD, HIV infection was associated with an increased odds of PTD [adjusted 
odds ratio (AOR) 2.03; 95% CI: 1.33, 3.10] but not LBW (AOR 1.47; 95% CI: 0.90, 2.40) 
(Table 3). 
 
Among HIV-infected women (comparisons B and C), there was a similar distribution of 
gestational age and birthweight subgroups, with most being late or moderately preterm 
and/or LBW (Table 2).  Birth outcomes did not vary appreciably in comparison B 
(initiating ART before pregnancy, n=477 vs. initiating in pregnancy, n=799): PTD (AOR 
0.70; 95% CI: 0.45, 1.07); LBW (AOR 0.72; 95% CI: 0.43, 1.21); SGA (AOR 1.05; 95% CI: 
0.58, 1.91) (Figure 2; Table 3).  Results were similar for comparison C (Figure 2; Table 3).  
In addition, the findings did not change appreciably when those comparisons were 





Among term infants, similar proportions were AGA (87% vs 88%) and SGA (13% vs 12%), 
comparing those born to HIV-infected and HIV-uninfected women.  Likewise, the 
preterm infants the proportion who were AGA (87% vs 84%) and SGA (13% vs 16%) was 
similar in the HIV-infected and HIV-uninfected women. 
 
Among normal birthweight infants, the proportions of term SGA were similar in HIV-
infected and HIV-uninfected women (6% vs 8%), while differences were observed in the 
proportions of term AGA (69% vs 76%) and preterm AGA (10% vs 5%).  Among the LBW 
infants, the proportions of term SGA (4% vs 3%), preterm SGA (3% vs 2%) and preterm 
AGA (8% vs 6%) were similar in the HIV-infected and HIV-uninfected women 
(Supplemental Figure 1). 
 
Subgroups of antiretroviral agents 
Because the associations between ART and birth outcomes may depend on choice of 
ARV, we carried out the same comparisons restricted to subgroups by antiretroviral 
agents.  The incidence of PTD, LBW and SGA were not appreciably different among 
women on EFV-based regimens compared to the total HIV-infected sample 
(Supplemental Table 1).  Following adjustment for age, parity, height and previous PTD, 
HIV infection was associated with an increased odds of PTD (AOR 1.97; 95% CI: 1.27, 
3.04) but not LBW (AOR 1.51; 95% CI: 0.91, 2.48).  Among HIV-infected women 
(comparison B), a higher incidence of PTD was observed among women conceiving on 
EFV-containing regimens (29%) compared to those initiating EFV-containing regimens 
during pregnancy (21%).  This difference in PTD persisted following adjustment for 
confounders (AOR 0.60; 95% CI: 0.39, 0.94) (Supplemental Table 2).  When comparisons 
were restricted to women initiating ART in pregnancy (comparison C), no differences 
were observed.  
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When analysis was restricted to women on PI-based regimens, a higher incidence of PTD 
(34% vs 13%) was observed in the HIV-infected (n=29) compared to HIV-uninfected 
women (n=278) (Supplemental Table 3).  This incidence in women on PI-based regimens 
(34%) was higher than that observed in HIV-infected women in the unrestricted (22%) 
and EFV-based analyses (23%).  In multivariable analysis, HIV infection was associated 
with an increased odds of PTD (AOR 4.46; 95% CI: 1.55, 12.83) but not LBW or SGA 
(Supplemental Table 4).  When women on PI-based regimens were compared to women 
on any NNRTI regimens, a higher incidence of PTD in women on PI-based regimens was 
noted (36% vs 24%) (Supplemental Table 5).   
 
Subgroups by gestation at first ANC visit 
When analysis was restricted to women who entered ANC before 20 weeks gestation in 
whom gestational estimation is likely to be most accurate, results for each comparison 
mirrored those of the main analysis.  A higher incidence of PTD (22% vs 9%) and LBW 
(15% vs 7%) was observed in HIV-infected (n=582) compared to HIV-uninfected women 
(n=128) while the frequency of SGA deliveries (12% vs 11%) was similar (Supplemental 
Table 6).  In multivariable analysis, HIV infection was associated with an increased odds 
of PTD (AOR 2.75; 95% CI: 1.38, 5.48) (Supplemental Table 7), however the association 
with LBW (AOR 2.19; 95% CI: 0.97, 4.94) did not persist.  Among HIV-infected women 
there were no differences observed between women initiating ART before pregnancy 
compared to those initiating during pregnancy (comparison B).  Similarly when 
comparisons were restricted to women initiating ART in pregnancy (comparison C), no 






In this cohort of HIV-infected and -uninfected pregnant women seeking ANC at a large South 
African public sector primary care facility, PTD appeared consistently associated with HIV 
infection and ART use, with HIV-infected women receiving ART approximately twice as likely to 
deliver preterm compared to HIV-uninfected women.  We found few appreciable differences 
in adverse birth outcomes between women initiating ART during pregnancy versus those  
initiating ART before pregnancy , though in subgroup analyses restricted to EFV-based 
regimens PTD appeared to be more likely in women conceiving on ART compared to those 
initiating during pregnancy. 
 
Our finding for a higher frequency of PTD in HIV-infected women regardless of timing of ART 
use is consistent with several previous studies from African populations as well as from high-
income countries (4, 17, 20).  However the PTD incidence among both HIV-infected (22%) and 
HIV-uninfected (13%) women observed here is higher than previous estimates for South Africa 
(approximately 10%) (31).  These results raise concern as PTD is the most common cause of 
neonatal morbidity and mortality globally (32), particularly in LMICs (4, 33).  Nonetheless, a 
larger proportion of our PTDs occurred later in gestation (>32weeks), which is somewhat 
reassuring (24, 34). 
 
We did not observe any differences in the proportions of term or preterm SGA or any 
significant associations with SGA across any of the three major analytic comparisons.  The lack 
of association between HIV status and SGA is different from a study in Botswana during the 
NVP-based ART era (4); however our findings were similar to those from another recent study 
in Botswana which evaluated TDF+FTC+EFV (11). In LMIC, SGA is usually a result of intrauterine 
growth restriction (IUGR) which leads to LBW as opposed to being normally grown but small 
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because of PTD (constitutionally small) (35).  IUGR in these settings tends to be caused by 
extrinsic factors and is late onset (>32 weeks) (36); given our higher frequency of late PTD (34-
37 weeks), our SGA findings could be a result of a reduction in the time for the effects of late 
onset growth restriction to take place because of earlier delivery.  Consequently any 
reductions in birthweight would be insufficient to achieve the definition of SGA.   
Overall among all HIV-infected women, we found that timing of initiation of widely used 
NNRTI-based regimens, before or during pregnancy, was not associated with adverse birth 
outcomes (PTD, LBW and SGA).  A study in Cameroon came to similar conclusions in terms of 
PTD (19), however our overall results differ from a number of previous studies that have 
demonstrated an increased risk of PTD and/or LBW either in women initiating ART before 
pregnancy (9, 37); or in women initiating during pregnancy (5).  There are concerns that 
previous studies comparing timing of ART initiation and adverse birth outcomes did not take 
into account gestational age at ART initiation, as women initiating ART later in pregnancy do 
not have equal opportunity to experience different outcome compared to those who initiated 
earlier or before pregnancy.  As part of our subgroup analyses we restricted the analysis to 
women who initiated before 26 weeks and those who experienced an outcome after 26 
weeks; these results were similar to the results of the overall analysis.   
One explanation for the lack of associations observed in our study could be the relatively high 
overall incidence of PTD (22%), possibly obscuring a weak signal for increased adverse birth 
outcomes among the women who initiated ART earlier during pregnancy.  It should be noted 
that in subgroup analyses, when restricted to EFV-based regimens women who initiated ART 
before pregnancy were at increased risk of PTD compared to those  initiating during pregnancy 
which is consistent with previous studies which demonstrated an increased risk of PTD and/or 
LBW in women on ART initiated before pregnancy (9, 37).  Given missing regimen data, 
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particularly among younger women, this subgroup analysis requires cautious interpretation 
given that previous studies have shown that differences in birth outcomes between initiating 
ART before pregnancy compared to those initiating during pregnancy may be largely 
attributable to differences in other risk factors for adverse outcomes such as gravidity (4) and 
maternal age.  
 
Despite the global use of TDF+FTC+EFV, few studies to date have investigated the effect of this 
regimen in pregnancy on birth outcomes.  Our results are consistent with a recent study of a 
national program using this regimen in Botswana (11) suggesting this regimen is unlikely to 
worsen rates of adverse birth outcomes.  Despite observing no overall differences in adverse 
birth outcomes by timing of ART initiation or with NNRTI use, there is some suggestion in these 
results of increased risk linked to the use of PI-based regimens consistent with previous studies 
(14, 38).  PIs may cause increased adverse birth outcomes via mechanisms related to 
interference with the adrenal system, implicated in the spontaneous onset of labor (15), 
and/or reductions in progesterone levels during pregnancy which could affect fetal growth 
(39).  To investigate this potential effect here, we compared women using PI-based to those 
using NNTRI-based regimens and found a similarly increased risk of PTD among women using 
PI-based regimens, albeit with limited precision.    
 
We found notable differences in miscarriages and stillbirths between HIV-infected and HIV-
uninfected women. Stillbirths appeared more likely among HIV-infected women, consistent 
with a meta-analysis demonstrating a nearly fourfold increase in stillbirths among HIV-exposed 
pregnancies (3).  Conversely, miscarriage appeared more likely in the HIV-uninfected women 
than HIV-infected women, a finding that is unexpected given that HIV status is often associated 
with early pregnancy loss (3).  In considering the latter finding, it is critical to note that these 
data – with enrolment of women as they present for routine care at a range of gestations – are 
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not ideal for examining early pregnancy loss, and in turn, this finding should be approached 
with caution.   
 
Interpretation of these data requires consideration of several strengths and limitations.  This 
study of a public sector primary care population allowed examination of the impact of ART 
initiation across a range of gestations, compared to clinical trials where gestation at ART 
initiation is often fixed.  Furthermore, the observational nature of our study provides good 
external validity of experiences in pregnancy.  These results are also substantially strengthened 
by the use of high quality measures of gestation (40), which contrasts with the reliance on SFH 
and/or LMP throughout previous analyses.  Ultrasonography for gestational age determination 
has been shown to be highly reproducible up to early second trimester (40).  Since we enrolled 
women entering ANC throughout pregnancy we conducted sub analyses restricted to women 
entering ANC <20 weeks which did not affect our findings.  A major limitation of our study is 
that our sample size is limited for certain subgroup analyses (including by ART regimen).  We 
were also unable to directly measure birthweight and relied on data abstraction from routine 
records; although this approach is widely used in research, it may contribute to random 
measurement error, potentially attenuating findings for LBW and SGA outcomes.  In addition, 
we had missing regimen data for women initiating ART before pregnancy; this is a result of the 
design of the parent study that collected less information on these women compared to those 
initiating during pregnancy.  
 
This research focuses on widely used NNRTI-based regimens which include TDF+FTC+EFV, the 
first-line regimen currently recommended by the WHO and the most commonly used 
combination of antiretroviral drugs globally.  However as new antiretroviral agents become 
more widely available it will be critical to continue to evaluate birth and long term outcomes 
associated with in utero ART exposure.  This includes both ongoing epidemiological research as 
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well as investigations of the pathophysiologic mechanisms that may lead HIV infection and/or 
antiretroviral use to cause prematurity and/or growth restriction.  
 
In summary, with the large and rapidly increasing number of HIV-infected taking ART during 
pregnancy around the world, our study suggests that current NNRTI-based regimens are 
unlikely to further increase adverse birth outcomes.  However, given the limited data on 
TDF+FTC+EFV, and the results of the EFV-based subgroup analyses, more studies investigating 
this regimen according to timing of ART initiation is required in representative cohorts.  These 
data highlight the high incidence of PTD among HIV-infected women on ART, pointing to a 
significant public health problem and an important consideration for the long-term health of 
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Key Messages 
 Several studies have suggested that antiretroviral therapy (ART) use in pregnancy may
contribute to adverse birth outcomes but there are few data from sub-Saharan Africa where HIV
is most prevalent.
 In this cohort of 1554 women enrolled in routine public sector care in Cape Town, HIV-infected
women had higher incidence of adverse birth outcomes (preterm and low birth weight delivery)
compared to HIV-uninfected women.  There appeared to be no associations between the timing
of antiretroviral initiation before or during pregnancy and birth outcomes, although some of the
comparisons may have been limited by lack of power.
 While these data suggest that first-line ART regimens (TDF+FTC+EFV) appear to be safe during
pregnancy, the high incidence of preterm delivery among HIV-infected women on ART remains a
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Figure 1. Birth outcomes by HIV/ART exposure status among women in the cohort 
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1st half of 2nd 
Trimester 
N=289 







Age, years        <0.001 
 ≤24 103 (34) 285 (19) 55 (10) 51 (27) 69 (24) 62 (24) 48 (25)  
 25-29 84 (28) 472 (32) 152 (27) 72 (39) 107 (37) 72 (28) 69 (36)  
 ≥30 110 (37) 720 (48) 358 (63) 63 (34) 110 (38) 116 (45) 73 (38)  
 Median (IQR) 27 (23-32) 29 (26-34) 31 (28-35) 27 (24-31) 28 (25-32) 29 (25-32) 29 (25-33)  
Education (Finished High School) 119 (40) 402 (27) 127 (22) 60 (32) 90 (31) 78 (30) 47 (25) <0.001 
Employment Status         0.002 
 Employed 139 (46) 557 (37) 214 (37) 88 (47) 118 (41) 89 (35) 48 (25)  
SES        0.66 
 Lowest 91 (30) 451 (30) 180 (31) 50 (27) 73 (25) 80 (31) 68 (36)  
 Medium 94 (31) 539 (36) 216 (38) 65 (35) 99 (34) 89 (35) 70 (37)  
 Highest 95 (32) 504 (34) 176 (31) 71 (38) 117 (40) 87 (34) 53 (28)  
Obstetric Characteristics 
Gestation, weeks         
 Median (IQR) 21 (16 – 27) 21 (15-27) 21 (15 – 28) 10 (8-12) 18 (16-19) 24 (22-25) 32 (26-35) - 
Height, cm        0.9 
 ≤155 85 (28) 444 (30) 163 (29) 60 (32) 92 (32) 79 (31) 50 (26)  
 156-161 90 (30) 464 (31) 170 (30) 72 (39) 89 (31) 69 (27) 64 (34)  
 ≥162 73 (24) 353 (24) 142 (25) 33 (18) 68 (24) 59 (23) 51 (27)  
 Mean (SD) 158 (8) 158 (7) 158 (7) 158 (7) 157 (7) 158 (7) 158 (6)  
Gravidity        0.005 
 1 72 (24) 244 (16) 63 (11) 38 (20) 64 (22) 48 (19) 31 (16)  
 2 101 (34) 544 (36) 196 (34) 81 (44) 109 (38) 90 (35) 68 (36)  
 ≥3 14 (47) 706 (47) 313 (55) 67 (36) 116 (40) 118 (46) 92 (48)  
 Median (IQR) 2 (2-3) 2 (2-3) 3 (2-3) 2 (2-3) 2 (2-3) 2 (2-3) 2 (2-3)  
Parity        0.006 
 0 75 (25) 259 (17) 68 (12) 43 (23) 65 (22) 50 (20) 33 (17)  
 1 100 (33) 558 (37) 202 (35) 79 (42) 117 (40) 94 (37) 66 (35)  
 ≥2 122 (41) 677 (45) 302 (53) 64 (34) 107 (37) 112(44) 92 (48)  
 Median (IQR) 1 (0-2) 1 (1-2) 2 (1-2) 1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2)  
Previous Miscarriage* 8 (3) 204 (14) 104 (18) 36 (19) 34 (12) 20 (8) 10 (5) <0.001 
Previous Preterm* 6 (2) 107 (7) 47 (7) 11 (6) 21 (7) 8 (3) 20 (10) 0.001 
HIV  
Current ART regimen, self-report        <0.001 
 TDF-3TC-EFV  1116 (87) 197 (34) 186 (100) 288 (99) 256 (100) 189 (99)  
 TDF-3TC-NVP  57 (4) 56 (10) 0 0 0 1 (0.5)  
 Other NNRTI-based regimen  72 (6) 71 (12) 0 1 (0.4) 0 0  
 PI-based regimen  33 (3) 32 (6) 0 0 0 1 (0.5)  
CD4 cell count, (cells/µL)        0.38 
 ≤ 200  213 (14) 65 (12) 29 (16) 44 (16) 47 (19) 28 (15)  
 201-350  426 (29) 167 (30) 52 (29) 90 (32) 70 (28) 47 (26)  
 351-500  384 (26) 154 (28) 42 (23) 75 (27) 65 (26) 48 (26)  
 >500  423 (28) 167 (30) 58 (32) 72 (25) 67 (26) 59 (31)  
 Median (IQR)   396 
(271-524) 
379 
(256 – 552) 
361 
(246 – 504) 
357 




Median HIV RNA Viral Load (log10 
copies/ml) 













*among women with a previous pregnancy 
**P values refer to the comparisons across exposure categories: HIV-uninfected, Initiation before pregnancy, Initiation during pregnancy (all four time periods) 
All variables, with the exception of height and ART regimen, had <3% missing data. For height, 16% (n=284) of data was missing with similar proportions of missing 
data across all comparison groups. For ART regimen, 14% (n=216) of data was missing and this was among the women who initiated ART before pregnancy 
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1st half of 2nd 
Trimester 
N=246 






Gestational Age (weeks)   <0.0001      0.001 
 Term (≥ 37) 242 (87) 986 (78)  358 (75) 111 (76) 197 (80) 187 (81) 133 (75)  
 Any Preterm (< 37) 36 (13) 285 (22)  115 (24) 34 (23) 49 (20) 43 (19) 44 (25)  
  Late Preterm (34-37) 21 (8) 167 (13)  69 (14) 19 (13) 29 (12) 24 (10) 26 (15)  
  Moderately Preterm (32-
34) 
13 (5) 91 (7)  37 (8) 9 (6) 16 (7) 11 (5) 18 (10)  
  Very Preterm (28-32) 2 (0.7) 27 (2)  9 (2) 6 (4) 4 (2) 8 (3) 0  
          
Birthweight (grams)   0.03      0.68 
 Normal (≥2500) 252 (91) 1085 (85)  402 (84) 118 (81) 214 (87) 199 (87) 152 (86)  
 Any LBW (<2500) 26 (9) 181 (14)  70 (15) 27 (18) 31 (13) 28 (12) 25 (14)  
  LBW (2500-1500) 23 (8) 157 (12)  61 (13) 23 (16) 27 (11) 21 (9) 25 (14)  
  Very LBW (<1500) 3 (1) 24 (2)  9 (2) 4 (3) 4 (2) 7 (3) 0  
 Mean (SD) 3199 (548) 3052 (580) 0.003 3090 (602) 3080 
(641) 
3120 (533) 3130 (574) 3150 (531) 0.63 
          
Size for Gestational Age 
(centile) 
  0.013      0.011 
 LGA (>90th) 35 (13) 112 (9)  56 (12) 13 (9) 13 (5) 11 (5) 19 (11)  
 AGA (10th – 90th) 211 (76) 984 (77)  356 (75) 105 (72) 202 (82) 190 (83) 131 (74)  
 SGA (<10th) 31 (11) 112 (9)  53 (11) 22 (15) 25 (10) 22 (10) 25 (14)  
          
LBW – Low Birthweight, LGA – Large for Gestational Age, AGA – Appropriate for Gestational Age, SGA – Small for Gestational Age 
*P values refer to comparisons between women who initiated ART before pregnancy vs during pregnancy (not expanded into the 4 time periods) 
All the variables had <4% missing data, with similar proportions of missing data across the comparison groups 
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Figure 2.  Incidence of preterm, low birth weight and small for gestational age deliveries by HIV status and timing of ART initiation before and during pregnancy 





Table 3. Adjusted associations between HIV/ART status and adverse birth outcomes 
Outcome Measure Comparison A* 
(Ref category: HIV-uninfected) 
Comparison B** 
(Ref category: Before pregnancy) 
Comparison C** 
(Ref Category: P1: <14weeks) 
AOR [95% CI] P value AOR [95% CI] P value AOR [95% CI] P value 
Preterm Delivery 
(<37 weeks) 
HIV-infected 2.03 (1.33–3.10) 0.001 During pregnancy 0.70 (0.45–1.07) 0.102 P2 0.91 (0.52–1.60) 0.75 
P3 0.79 (0.44–1.42) 0.442 
P4 1.41 (0.79–2.51) 0.244 
Low Birth Weight 
(<2500g) 
HIV-infected 1.47 (0.90–2.40) 0.124 During pregnancy 0.72 (0.43–1.21) 0.217 P2 0.70 (0.36–1.35) 0.283 
P3 0.68 (0.34–1.34) 0.264 
P4 1.15 (0.59–2.28) 0.669 




HIV-infected 0.91 (0.58–1.43) 0.695 During pregnancy 1.05 (0.58–1.91) 0.861 P2 0.77 (0.38–1.56) 0.461 
P3 0.74 (0.35–1.54) 0.414 
P4 1.62 (0.79–3.30) 0.184 
Comparison A (HIV-infected vs HIV-uninfected), Comparison B (ART initiated before pregnancy vs ART initiated during pregnancy), Comparison C (ART initiated during pregnancy at 4 time points: P1 (<14 weeks), P2 (14-20 weeks), 
P3 (21-27 weeks), P4 (>28weeks) 
* adjusted for age, maternal height, parity and previous PTD
** adjusted for age, maternal height, parity and previous PTD, CD4 count and VL
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SECTION D: APPENDICES 
MCH-ART: Demographics & Medical History, Phase 1
 
PID: 1 - __ __ __ __ - __ __Xhosa-English of Version 3.0, 15 October2013
Visit Date: __ __/__ __ __/__ __ __ __ 
1.  Mingaphi iminyaka yakho 
What is your age?   Age:     _________Iminyaka/years 
2.  Uloluphi uhlanga 
What population group do you belong to? 
UmAfrika African = 1 
Indiya Indian = 2 
Umntu webala Coloured = 3 
Umlungu White = 4 
Olunye = 5, cacisa: _________________ 
Other specify 
3.  Uthetha oluphi ulwimi ekhayai? 
What language do you speak at home? 
isiXhosa = 1 
isiZulu = 2 
isiBhulu Afrikaans = 3 
isiNgesi  English = 4 
Olunye = 5, cacisa: _________________ 
Other specify 
4.  
Lelephi elona banga liphezulu 
oliphumeleleyo? 




Imfundo enomsila/ Postsecondary:__________ 
5.  Ngoku uyasebenza okanye uyafunda
Are you currently working and /or studying? 
Hayi No = 0  Gqithela ku Q7 SKIP to Q7
Ewe Yes = 1 
6. 
Ukuba nguEwe, yeyephi kwezi zilandelayo 
echaza, bhetele ukuba wenza ntoni? 
If yes, which of one the following best describes what you do? 
Khetha ibenye /Choose one only 
Ndiphangela isigxina = 1 
Employed full-time 
Ndiphangela mangqaphangqapha = 2 
Employed part-time 
Ndiphangela izingxungxo/ ndingumatheng ‘ethengisa = 3 
Informal job/hawker 
Uhamba isikolo/ ungumfundi = 4 
Attending school/learner 
Uhamba isikolo semfundo enomsila = 5 
Attending tertiary education facility 
7. 
Ngowuphi owona mthombo wemali kwikhaya 
lakho? 
What is the MAJOR source of income for your household? 
Khetha ibenye /Choose one only 
Ayikho =0 
None 
Umsebenzi osisigxina =1 
Full-time employment 
Umsebenzi wamaangqaoha-ngqapha =2 
Part-time employment
Umsebenzi wezingxungxo/ umthengisi =3 
Informal employment 
Imali yesibonelelo sokukhuba zeka karhulumente= 4 
Disability grant 
Imali yesibonelelo karhulumente =5 
Social grant 
Umhlala phantsi =6 
Pension 








Andazi = 9 
Don’t know 
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8.  Uhlala kwikhaya elinjani? 
What kind of home do you live in? 
Ityotyombe/ uhlaliso olungahlelwanga = 1 
Shack/informal dwelling 
Indlu yesitena = 2  
Formal house 
Ifleti/ indlu kamaspala = 3 
Flat/council home 
Enye = 4, chaza:__________ 
Other, specify 
9.  
Ingaba indlu yakho inazo 
ezi zinto zilandelayo: 
Does your house have the following: 
Read and answer for all 
a. Indlu 
yangasese   
A toilet inside 







Hayi/No =0                                     
Ewe/Yes =1 
c. Umbane  
Electricity inside 
Hayi/No =0                                     
Ewe/Yes =1 
d. Isikhenkcisi  
A refrigerator 
Hayi/No =0                                     
Ewe/Yes =1 
e. Umnxeba  
A telephone 
Hayi/No =0                                     
Ewe/Yes =1 
f. Umabona 
kude   
A television 
Hayi/No =0                                     
Ewe/Yes =1 
10.  
Bangaphi abantu abahlala kule ndlu bedibene 
nawe(abadala,abancinci)? 
Including yourself, how many people (adults and children) live 
in your house? 
Inani labantu: ________ 
# of people: 
11.  
Bangaphi abadala (iminyaka-16  
nangaphezulu)bedibene nawe abahlala kule 
ndlu? 
How many adults (aged 16 or older), including you, live in your 
house? 
Inani labadala:_________ 
# of adults 
12.  
Bangaphi abantwana (iminyaka -15 
nanganeno ) abahlala nawe? 
How many children (aged 15 and under) live in your house? 
Inani labantwana:__________ 
# of children 
13.  
Ukhulelwe kangaphi (kudibene nesi isisu)? 
How many times have you been pregnant (including current 
pregnancy)? 
inani lokukhulelwa: _________ 
# of pregnancies: 
14.  
Ingaba ubuzama ukuba nosana ngelixesha 
ufumanisa ukuba ukhulelwe (Kwesi isisu)? 
Were you trying to have a baby when you found out you were 
pregnant (in this pregnancy)? 
Hayi/No = 0                                     
Ewe/Yes = 1 
Andazi/I don’t know = 9 
15.  Bangaphi abantwana obazeleyo? 
How many children have you given birth to? 
Inani labantwana:________ 
# of children 
Ukuba = 0, Gqithela ku Q20  
If 0, SKIP to Q20 
16.  Bangaphi kwaba bantwana abaphilayo? 
How many of these children are living? 
Inani labantwana:________ 
# of children 
17.  
Bangaphi kwaba bantwana abahlala nawe 
ngoku? 
How many of these children currently live with you? 
Inani labantwana:________ 
# of children 
18.  
Bangaphi kwaba bantwana ekufumaniseke 
bakho ukuba baphila nentsholongwane? 
How many of your children have tested HIV-positive? 
Inani labantwana abaphila nentsholongwane:________ 
# of HIV-positive children 
19.  
Bangaphi kwaba bantwana baphila 
nentsholongwane abasaphilayo? 
How many of these children who have tested HIV- positive are 
currently living? 
Inani labantwana abaphila nentsholongwane abaphilayo 
ngoku: _______ 
# of HIV-positive children currently alive 
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20.  Uya thandana ngoku? 
Are you currently in a relationship? 
Hayi/No = 0 Gqithela ku Q25 
SKIP to Q25                               
Ewe/Yes= 1 
21.  Ungaluchaza njani uthando lwakho? 
How would you describe your current relationship? 
Utshatile = 1 
Married 
Anditshatanga ,ndiya hlalisana =2  
Not married, living together 
Nditshatile, asihlali kunye = 3 
 Married, not living together   
Anditshatanga, asihlali kunye = 4 
Not married, not living together  
Enye = 5, cacisa:__________ 
Other, specify 
22.  
Lileshe ellingakanani unobudlelwana 
nalomntu? 
How long have you been in a relationship with this person? 
Ixesha         Inyanga Months_________ 
Duration in:         Iminyaka Years _______ 
23.  
Ingaba eli qabane lakho ngutata womnye 
wabantwana bakho(kunye nalo 
umkhulelweyo)? 
Is your current partner the parent of any of your children? 
(including current pregnancy) 
Hayi/No = 0                                     
Ewe/Yes = 1 
24.  
Ulichazele na iqabane lakho ngesimo sakho 
sentsholongwane? 
Have you disclosed your HIV status to your current partner? 
Hayi/No = 0                                     
Ewe/Yes = 1 
25.  
Ubukhe wabelana ngesondo nabanye abantu 
ingenguye lomntu uthandana naye? 
In the last 12 months have you had any sexual 
relationships/sexual partners? (if in a relationship then other 
than this partner) 
Hayi/No = 0  Gqithela ku Q28                                   
 SKIP to Q 28 
Ewe/Yes = 1 
26.  
Bunjani ubudlelwanebakho namanye 
amaqabane ngaphandle kweqabane lakho 
langoku ukuba akhona? 
What is the nature of your relationship(s)? (other than current 
partner if applicable) 
 
Rhangqa  konke okungqamene nawe. 
Mark all that apply. 
a. Umlingane/nditshatile 
Spouse/ married 
b. Iqabane lam  
Boyfriend 
c. Iqabane lethutyana  
Casual Partner/One Night Stands  
d. Omnye ,cacisa:_________________  
Other, specify  
27.  
Ubaxelele aba bantu wabelana nabo 
ngesondo ukuba uphila nentsholongwane? 
Have you disclosed your HIV status to any of these other 
sexual partners? 
Hayi/No = 0                                     
Ewe/Yes = 1 
28.  
Ubuqala ukufumanisa ukuba unentsholongwa 
kagawulayo kolumitho okanye phambi kokuba 
ukhulelwe? 
Did you first test HIV positive in this pregnancy or before this 
pregnancy?  
Koku ukukhulelwa =1   Gqithela ku Q32 
In his pregnancy                               SKIP to Q32 
Phambi koku ukukhulelwa =2  
Before this pregnancy 
29.  
Kwakunini ukuqala kwakho ukufumanisa 
ukuba unentsholongwane kagawulayo? 
When did you 1st test HIV-positive? 
Umhla:___ Inyanga:_____ Unyaka:______ 
Day                   Month                         Year 
30.  Kwakutheni ukuze oluhlolo lwenziwe? 
Why was this test conducted? 
Ndivavanywe ngelixesha ndikhulelweyo = 1  
Tested during pregnancy  
VCT/Ndandifuna ukuvavanywe =2  
VCT/Wanted to be tested 
Ndafunyaniswa ndinesifo sephepha (TB) = 3 Diagnosed with 
TB 
Ndangeniswa esibhedlele = 4  
Admitted to the hospital 
Enye = 5, cacisa:__________ 
Other, specify 
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31.  
Ingaba wawukhulelwe ukuqala kwakho 
ukufumane ukuba unentsholongwane 
kagawulayo? 
Were you pregnant when you first tested HIV-positive? 
Hayi/No = 0 
Ewe/Yes = 1
32.  
Wakhe wanazo iziphumo ezingena chaphaza 
kuvavanyo lwentsholongwane kagawulayo?
Have you ever tested negative on an HIV test? 
Hayi/No = 0  Gqithela ku Q36 
  SKIP to Q36   
Ewe/Yes = 1 
33.  
Ugqibele nini ukuba neziphumo 
ezingenachaphaza zovavanyo 
lwentsholongwane kagawulayo? 
When did you last test HIV-negative? 
Umhla:___ Inyanga:_____ Unyaka:______ 
Day       Month   Year 
34.  
Kwakutheni ukuze  uvavanywe ngelo xesha? 
What was the reason for you doing the HIV 
test?
Why did you test at that time? 
Ndivavanywe ngelixesha ndikhulelweyo = 1 
Tested during pregnancy 
VCT/Ndandifuna ukuvavanywe =2 
VCT/Wanted to be tested 
Ndafunyaniswa ndinesifo sephepha (TB) = 3 Diagnosed with
TB 
Ndangeniswa esibhedlele = 4 
Admitted to the hospital
Enye = 5, cacisa:__________ 
Other, specify 
35.  
Wawukhulelwe ngeloxesha uvavanyelwa  
intsholongwane? 
Were you pregnant at the time of that test? 
Hayi/No = 0    
Ewe/Yes = 1
36.  
Wakhe waxelela nabanina ukuba 
unentsholongwane kagawulayo? 
Have you told anyone that you are HIV-positive? 
Hayi/No = 0  Gqithela ku Q39 
  SKIP to Q39   
Ewe/Yes = 1 
37.  
Ngawaphi amlungu osapho lwakho owaxeleleyo ngesimo sakho sentsholonwane? 
Which of your family members have you told about your HIV status? 
Nceda phendula lombuzo ngelungu ngalinye losapho oludweliswe ngezantsi. 
Please answer this question for each of the family members listed below. 
Wamxelele u_ _ _ _ _ _ _ ukuba unentsholongwane kagawulayo? 
Have you told your _______ that you are HIV positive? 
a.  Umyeni/iqabane
Husband/partner/boyfriend 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
b.  Umama 
Mother 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
c.  Utata 
Father 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
d.  Udade
Sister 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
e.  Umtakwenu
Brother 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
f.  Intombi
Daughter 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
g.  Unyana
Son 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
h.  Umalume
Uncle 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
i. U-anti
Aunt 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
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j.  Umza wesikhomo  
Male cousin 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
k.  Umza wesikhomokazi    
Female cousin 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
l.  Enye indoda yalapha 
Other male family member 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
m.  Esinye isikhomokazi   
Other female family member 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
38.  
Ngaphandle kwabantu bakowenu  aba badweliswe ngentla,ngubani omnye umntu owamxelelyo ukuba 
uphila nentsholongwane?(funda uphendule yonke imibuzo) 
Aside from family members listed above, who else have you told about your HIV status? (read and answer for all ) 
a.  Amanesi/ogqira   
Health professionals 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
b.  
Iqumru lenxaso labantu abaphila 
nentsholongwane 
Support group 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
c.  
Umntu owabelana naye ngesondo ongahlali 
naye 
A sexual partner who does not live with you 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
d.  Isihlobo  
Friends 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
e.  Inkokheli ngokwa kwamoya 
Spiritual leader 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
f.  Umntu okuqashileyo/wayekuqashile  
Current or former employer 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
g.  Ukuchaza esidlangalaleni 
Public disclosure/ community 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
h.  Abanye, chaza: _______________ 
Other, specify 
Hayi/No = 0                                     
Ewe/Yes = 1 
N/A = 9 
39.  
Wakhe wakhulelwa phambi koku 
ukukhulelwa? 
Have you ever been pregnant before this pregnancy? 
Hayi/No = 0  Gqithela ku Q45 
                        SKIP to Q45                        
Ewe/Yes = 1 
40.  
Ngokuya ubukhulelwe ngaphambi koku 
ukukhulelwa wawuke wanikwa amayeza okhusela 
usana lungosuleleki yintsholongwane (ezeku 
khusela umntwana hayi amachiza okutho malalisa 
intsholongwane wobomi bonke) 
When you were pregnant before this pregnancy have you ever 
been given medication at the clinic to keep your baby from 
getting HIV infected? (prophylaxis NOT lifelong ART) 
Hayi/No = 0  Gqithela ku Q45 
                              SKIP to Q45                        
Ewe/Yes = 1 
41.  
Ukuba nguEwe, zingaphi izisu ufumane la 
machiza ngesisizathu? 
If yes, during how many pregnancies have you received 
medication for this purpose? 
Inani lezisu:______ 
# of pregnancies 
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42.  
Kwezi zisu siyi____ofumene kuzo amachiza, 
zingaphi izisu otye kuzo iipilisi ngelixesha 
ubelekayo qha? 
For the ___ pregnancies that you received medication, For how 
many pregnancies did you take pills while you were pregnant 
and for how many pregnancies did you take pills only at 
delivery? 
Ngoku wawubeleka 
Only at Delivery (Nevirapine) #:___________ 
Ngelixesha ukhulelwe 
While you were pregnant (AZT)? #: _______ 
43.  
Bekunini ukugqibela kwakho ukufumana la 
machiza ngesisizathu? 
When was the last time that you received medication for this 
purpose? 
Umhla:___ Inyanga:_____ Unyaka:______ 
Day                   Month                         Year 
44.  
Uwafumene phi la machiza ukugqibela 
kwakho? 
Where did you receive the medication the last time? 
Igama lekliniki:_______________ 
Name of clinic:  
45.  
Wawuke wawathatha amachiza 
okuthomalalisa intsholongwane (awobomi 
bakho bonke) 
Have you ever taken triple drug antiretroviral therapy (lifelong 
ART)? 
Hayi/No = 0   Phela apha/End here                                
Ewe/Yes = 1 
46.  
Ukuba nguEwe, ingaba wawafumana 
amachiza okuthomalalisa intsholongwane 
ukugqibela kakho?  
If yes, where did you receive ART the last time? 
Igama lekliniki:_______________ 
Name of clinic:  
47.  
Uqale nini ukutya la machiza okuthomalalisa 
intsholongwane kagawulayo? 
When did you start taking ART? 
Umhla:___ Inyanga:_____ Unyaka:______ 
Day                   Month                         Year 
48.  
Usawatya amachiza okuthomalalisa 
intsholongwane kagawulayo? 
Are you still on ART? 
Hayi/No = 0   
Ewe/Yes = 1 SKIP to Q51 
49.  
Ukuba nguHayi,uyeke nini ukuwatya 
amachiza okuthomalalisa intsholongwane 
kagawulayo? 
If No, when did you stop taking ART? 
Umhla:___ Inyanga:_____ Unyaka:______ 
Day                   Month                         Year 
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50.  
Uyekele ntoni ukutya amachiza athomalalisa 
intsholongwane? 
Why did you stop taking ART? 
(rhagqa zonke ezibhekisa kuwe) 
Circle all that apply 
a. Ndaphelelwa ngumchiza andaya ukuyakuwalanda 
I ran out of medicine and didn’t go for refills 
b. Anencasa embi 
The medicine tastes bad 
c. Ndulibala 
   I just forgot 
d. Bendikhathazwa yimiphumela yawo 
I was worried about the side effects 
e. Bendingafuni abanye bandiqaphele ukuba nditya 
amachiza 
 I did not want others to notice me taking the medicine 
f. Ndandigula 
 I was ill 
g. Ndacinga ukuba andisawafuni nganto 
 Didn’t think I needed it anymore 
h. Bendicinga ndingahlala ndiphilile ngaphandle 
kwawo 
Can stay healthy without it  
i. Bendicinga ukuba lamayeza anganobu ngozi kum. 
I felt the medicine might be harmful to me 
j. Ndizive ndinoxinizelelo 
        I felt depressed 
k. Ndandiphilile 
        I was well 
l. Ebemaninzi la machiza ekufuneka ndiwathathe 
There was too much medicine to take 
m. Bendingekho ekhaya 
I was away from home   
n. Bendixakekile zezinye izinto 
I was busy with other things 
o. Ndiye ndafunda ukuba zikho ezinye iindlela 
endinganyanga okanye ndiphilise intsholongwane 
kagawulayo 
I learned that there are other ways to treat or cure HIV 
p. Enye, cacisa: ____________________________ 
Other, Specify 
51.  
Ubukhe watshaya isagarethi kulenyanga 
iphelileyo? 
Did you smoke cigarettes in the last month?  
Hayi No = 0  END 
Ewe Yes = 1 
52.  Utshaya isigarethi ezingaphi ngemini? How many cigarettes do you smoke in a day? #______________ cigarettes 
 
 
Date completed: _ _ /_ _ _ / _ _ _ _    Signed counsellor completing CRF: ______________ 
Date of QC: _ _ /_ _ _ / _ _ _ _           Signed measurement nurse: _________________ 
Page 7 of 7   Initials of counsellor: ________ 
IRB-AAAK8059
     for use until: 10/28/2015
IRB Approval Date: 10/29/2014












Page 1 of 3  Initials of counsellor: ___ 
This CRF is to be completed by women on ART only  
 Visit Date: __ __/__ __ __/__ __ __ __ 
1.  Yintoni igama lamachiza owatyayo? 
What are the names of the ARVs you are taking? 
 
2.  
Ukususela ukuqala kwakho ukutya amachiza, wawuke 
wawayeka na? 
Since you first started taking ART, have you ever stopped? 
Hayi No –> SKIP to Q5 
Ewe Yes 
3.  Mangaphi amaxesha uyeka uphinde uqalele ukutya amachiza?  
How many times have you stopped and restarted ART? 
Amaxesha: __________ 
# times 
4.  Bekunini ukugqibela kwakho ukuqalela amachiza? 
When did you restart ART the last time? 
Umhla:___ Inyanga:______ 
Unyaka:_______ 
Day                 Month                        Year 
5.  iART uzithatha kangaphi ngemini? 
How many times a day do you take your ART pills? 
Amaxesha: _____________ 
# of times 
6.  Zingaphi ipilisi ozityayo ngexesha? 
How many pills do you take each time? 
# Iipilisi:______________ 
# of pills 
7.  Mangaphi amachiza  entsholongwane ohlukeneyo owatyayo? 
How many different HIV medicines do you take? 
# amchiza:____________ 
# of medicines 
8.  
Oko waqala ukuwatya,ungazibeka kweliphi inqanaba lokutya 
ngendlela owawuyibonisiwe yokutya amachiza akho? 
Since you started taking them, how would you rate how well you usually do 
taking your HIV medicines in the way you are supposed to? 
Kakubi kakhulu=1 












Ngoku cinga ngentsuku ezi-30 ezidlulileyo.yeyiphi kwezi 
zilandelayo echaza eyona ndlela otya ngayo amachiza akho? 
Now think about the last 30 days. How would you rate how well you did taking 
your HIV medicines? 
Kakubi kunakuqala=1 
Worse than usual  
Kakuhle kunakuqala=2 
Better than usual 
Kuyafana njengesiqhelo=3 
About the same as usual 
10.  
Kwintsuku ezi-30 ezidlulileyo,zimini ezingaphi okhe walibala 
ukutya amchiza akho entsholongwana? 
In the last 30 days, on how many days did you miss at least one dose of any of 
your HIV medicines? 
Intsuku: _____________ (0-30) 
# of days 
11.  
Kwezi ntsuku zi-30 zidlulileyo uwatye  kakuhle kanjani amachiza 
akho entsholongwane njengohlobo omele ukuwatya ngalo? 
In the last 30 days, how good a job did you do at taking your HIV medicines in 
the way that you were supposed to? 
Kakubi kakhulu=1 
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12. 
Kwezi ntsuku zi-30 zidlulileyo,kukangaphi usitya amachiza akho 
entsholongwane  ngendlela omele kuwatya ngayo?
In the last 30 days how often did you take your HIV medicines in the way that you 







Ngesiqhelo = 4 
Usually 





Kunzima kangakanani ukutya amachiza akho entsholongwana 
ngendlela omele kukuwatya ngayo?








Not very hard 
Akunzimanga kwaphela =5
Not hard at all 
14. 
Kwintsuku ezi-30 ezidlulileyo ,zeziphi izinto ezibangele  ulibale, 
okanye  ezenze kubenzima ukutya amachiza akho?
In the past 30 days which of the following things made you miss a pill or made it 
hard for you to take your pills? 
Zifunde zonke.Urhangqe zonke ezikhe zakwehlele.
Read all. Circle as many as apply. 
a. Bendingekho ekhaya
Was away from home?
b. Zilahlekile
Lost your pills?
c. Bendixakekile ndisenza omnye
umsebenzi
Was busy with other things?
d. Ndilibele
Simply forgot?
e. Bezininzi ipilisi ebekufuneka
ndizitye
Had too many pills to take?
f. Bendifumana imiphumela
Was getting side effects?
g. Bendibaleka imiphumela okanye
ndingaziva mnandi
Wanted to avoid side effects or were feeling
bad?
h. Bendizinika ikhefu kwipilisi
Wanted to take a break from the pills?
i. Bendingafuni abanye bazi ukuba
nditya ipilisi
Did not want others to notice you taking
medication?
j. Kuye kwabakho utshintsho
kwindlela endisebenza ngayo
okanye ngendlela endiqhele
Had a change in daily routine or work
schedule?
k. Bendicinga ukuba ipilisi
ziyasebenza noba ezinye
andizityanga
Thought that the pills would still work even if
IRB-AAAK8059
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a few were missed? 
l. Bendiba amachiza ayingozi
Felt the drugs were toxic/ harmful?
m. Bendilele ngexesha lokutya ipilisi
Slept through dose time?
n. Ndizive ndingaphilanga
Felt sick or ill?
o. Ziye zandongamela
Felt overwhelmed?
p. Ndive ndino xinezelelo
Felt depressed?
Date completed: _ _ /_ _ _ / _ _ _ _    Signed counsellor completing CRF:___________ 
Date of QC: _ _ /_ _ _ / _ _ _ _                Signed Measurement Nurse: ____________
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        PID 1-__ __ __ __-__ __  




Initials of data abstractor 
 
 









Mothers date of birth 
 
(dd/mm/yyyy) 











Previous Pregnancies (per maternity chart) 
 
Year Gestation Delivery Weight Sex Outcome Complications 
       
       
       
       
       
       
 




Epilepsy Diabetes Cardiac TB Other Healthy 
Details of 
history: 
      
Other       
       
 
Screening CD4 date - NHLS  
Screening CD4 result - NHLS  
Screening CD4 date – PIMA  
Screening CD4 result - PIMA  
Patient on ART already?  Yes=1   No=0 
  
1C  MCH-ART Maternity Case Record Data Abstraction Form
MCH-ART data abstraction: Maternity Case records  
Version 2.0 1 September 2013        PID 1-__ __ __ __-__ __  
Details of Booking Examination 
 
Date of booking examination  dd/mm/yyyy) 
BP 
 
Systolic:   Diastolic:  
Height 
 














Pos=1     Neg=0 
ABO 
 
Enter blood group 
 
EDD Estimation 
EDD estimate #1 EDD (dd/mmm/yy) Gestational age (weeks) 
Type of assessment #1 
(circle one) 
 
Dates/ LNMP  SFH   USS 
Date of assessment #1 
(dd/mmm/yyyy) 
 
EDD estimate #2 
 
EDD (dd/mmm/yy) Gestational age (weeks) 
Type of assessment #2 
(circle one) Dates/ LNMP  SFH   USS 




EDD estimate #3 
 
EDD (dd/mmm/yy) Gestational age (weeks) 
Type of assessment #3 
(circle one) 
 
Dates/ LNMP  SFH   USS 











        PID 1-__ __ __ __-__ __  
Please circle and/complete answers for all questions NR = not recorded NA = not applicable 
1. Demography  
Source document  
Initials of data abstractor  
Date of data abstraction (dd/mm/yyyy) 
MCH-ART number  
Mothers surname  
Mothers date of birth (dd/mm/yyyy) 
Mothers provincial folder number  
Mothers date of delivery (dd/mm/yyyy) 
Patient details  
Where did the patient deliver? 
(Gugs MOU – Gugulethu MOU 
MMH - Mowbray maternity hospital 
GSH - Groot Schuur hospital) 
Gugs MOU=1                              MMH=2  
GSH=3                                          Other=4 




(please circle one) 
A=1             B=2             AB=3             O=4             NR=9 
Rhesus Pos-1             Neg=0            NR=9 
Syphilis test Pos-1             Neg=0            NR=9 
Estimated gestational age  weeks 
Gestational age estimated by 
(Please circle one) 
Dates=1          Palpation=2           SFH=3           USS=4  
2. Labour and delivery  
Method of delivery 
(C/S = caesarean section) 
NVD=1                                                     Forceps=2  
Vacuum=3                                              Elective C/S=4  
Emergency C/S=5 
Duration of rupture of membranes 
(NR if not recorded) 
mins 
If by C/S, indication for a C/S Fetal distress=1                                    Obstructed labour=2 
Twins/Triplets=3                                   Placenta praevia=4 
Pre-eclampsia/eclampsia=5                Previous C/S=6 
If by C/S, 
Was the C/S done after ROM? 
Yes=1             No=0              NR=9 
Is mother on any ARVs? Yes=1             No=0              NR=9 
If yes, describe  
Did mother receive any ARVs during 
labour? 
Yes=1             No=0              NR=9 
If yes, describe  
 
1D  MCH-ART Obstetric Record Data Collection Form
MCH-ART data abstraction: OBSTETRIC records 
Version 2.3 11
th
 February 2014  PID 1-__ __ __ __-__ __ 
3. Infant details
Was any resuscitation done to infant? Yes=1   No=0   NR=9 
Did infant have any birth injuries? Yes=1   No=0   NR=9 
Gender of infant Male=1    Female=0 
Outcome of infant Alive=1    Stillborn=2   Dead=3    NR=9 
Birth weight g 
Placental weight g 
Head circumference cm 
length cm 
Apgar scores 1 min 
5 min 
Did the infant receive NVP at birth? Yes=1   No=0   NR=9 
Did the infant receive polio vaccine? Yes=1   No=0   NR=9 
Did the infant receive BCG vaccine? Yes=1   No=0   NR=9 
4. Infant details of twin B. (fill only if twin pregnancy)
Was any resuscitation done to infant? Yes=1   No=0   NR=9 
Did infant have any birth injuries? Yes=1   No=0   NR=9 
Gender of infant Male=1    Female=0 
Outcome of infant Alive=1   Stillborn=2   Dead=3    NR=9 
Birth weight g 
Placental weight g 
Head circumference cm 
length cm 
Apgar scores 1 min 
5 min 
10 min 
Did the infant receive NVP at birth? Yes=1   No=0   NR=9 
Did the infant receive polio vaccine? Yes=1   No=0   NR=9 
Did the infant receive BCG vaccine? Yes=1   No=0   NR=9 
5. Discharge summary
Feeding option Breast=1   formula=2  NR=9 
If breastfeeding, was breastfeeding 
initiated successfully? 
Yes=1   No=0   NR=9 
Choice of family planning 
(TL –tubal ligation) 
Injectable=1   Oral=2 
IUCD=3        TL=4 
Other=5    If other, specify 
Date of discharge dd/mm/yyyy 
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2D MCH-ART ICAP IRB Approval 
November 1, 2015 
Elaine Abrams 
ICP ICAP - 823100X 
Mailman School of Public Health/ICAP 
722 West 168th Street 
MSPH 
Protocol Number: IRB-AAAK8059 
Title: Strategies to optimize antiretroviral therapy services for maternal & child health: the MCH-ART study 
Approval Date: 10/06/2015 Expiration Date: 10/05/2016 
Grant #: 1R01HD074558-01 
Dear Dr. Abrams, 
On October 6, 2015, the renewal for the above-mentioned study was reviewed and approved by expedited review, category #9, by the 
Chair of the Columbia University Medical Center Institutional Review Board #3. It is noted that study enrollment is permanently closed. 
Important Reminder: A request for continuation or completion of a research protocol is due at least 60 days before this research 
protocol’s expiration date, unless otherwise requested by the Board. This renewal was submitted on 09/24/2015 with an expiration of 
10/28/2015. 
The following study-related materials were approved: 
- MCH-ART MICS indicators Version 1_23April 2015_tp, attached 5/12/2015
- CBCL_pid- English, attached 5/12/2015
- CBCL Xhosa final sent ASEBA May 2008_pid, attached 5/12/2015
- Infant Dem and MH - Phase 3_18 months pp_V1.0 X-E_clean, attached 5/12/2015
- Qualitative Interview guide, 01October2014- Xhosa, attached 10/16/2014
- Qualitative Interview guide, 01October2014- English, attached 10/16/2014
- Phase 3 Maternal demo & Med hx, 12mo pp, 04August2014- Xhos, attached 9/9/2014
- In-depth interview ICF, 16May2014- Xhosa, attached 9/9/2014
- In-depth interview ICF, 16May2014- English, attached 9/9/2014
- Neurodevelopmental feedback form, 02July2014- Xhosa, attached 9/9/2014
- Neurodevelopmental ICF, 18July2014- Xhosa, attached 9/9/2014
- Neurodevelopmental ICF, 18July2014- English, attached 9/9/2014
- Infant Adherence, Phase 3 6-12 mo, Xhosa, attached 5/1/2014
- Infant Adherence, Phase 3 6wk&3mo, Xhosa- clean, attached 5/1/2014
- Infant Adherence, Phase 2 <7dayspp, Xhosa-clean, attached 5/1/2014
- Infant Demo & Med Hx, Phase 3 6wks, Xhosa- clean, attached 5/1/2014
- Infant Feeding, Phase 3 3mo-12mo, Xhosa- clean, attached 5/1/2014
- Infant Feeding, Phase 3 6wk, Xhosa-clean, attached 5/1/2014
- Infant Feeding, Phase 2 <7dayspp, Xhosa- clean, attached 5/1/2014
- Infant Demo & Med Hx, Phase 3 12mo, Xhosa- clean, attached 5/1/2014
- Infant Demo & Med Hx, Phase 3 9mo, Xhosa- clean, attached 5/1/2014
- Infant Demo & Med Hx, Phase 3 6mo, Xhosa- clean, attached 5/1/2014
- Infant Demo & Med Hx, Phase 3 3mo, Xhosa- clean, attached 5/1/2014
- Infant Demo & Med Hx, Phase 2 <7dayspp, Xhosa- clean, attached 5/1/2014
- Verbal Autopsy Tool, attached 5/1/2014
- Telephone Follow-up CRF, 09April2014, attached 5/1/2014
- Home Visit CRF, 24 April2014, attached 5/1/2014
- Food Security questionnaire- Xhosa, 25April2014, attached 5/1/2014
- Food Security questionnaire- English, 02April2014, attached 5/1/2014
- Resource Interview questionnaire- Xhosa, 25April2014, attached 5/1/2014
- Resource Interview questionnaire- English, 14April2014, attached 5/1/2014
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- Pt-provider relationship scale, Phase 2 (late 3rd)- Xhosa, attached 12/16/2013 
- Pt-provider relationship scale, Phase 2 (late 3rd)- English, attached 12/16/2013 
- Pt-provider relationship scale, Phase 2 (<7days)- Xhosa, attached 12/16/2013 
- Infant Adherence, Phase 2 <7dayspp, 29Sept13-clean, attached 11/6/2013 
- Anthropometry CRF, Phase 3 visits, 29Oct2013, attached 11/6/2013 
- Anthropometry CRF, Phase 2, <7 days pp, 29Oct 2013, attached 11/6/2013 
- Demo & Medical Hx, Phase 2, <7days pp, Xhosa, attached 7/3/2013 
- Demo & Medical Hx, Phase 2, <7days pp, attached 7/3/2013 
- Demo & Medical Hx, Phase 2, 3rd trimester, Xhosa, attached 7/3/2013 
- Demo & Medical Hx, Phase 2, 3rd trimester, attached 7/3/2013 
- Trauma & Abuse Assessment, Phase2, <7days pp, Xhosa, attached 7/3/2013 
- Trauma & Abuse Assessment, Phase 2, <7 days pp, attached 7/3/2013 
- Maternal Adherence, Phase 3, attached 7/3/2013 
- Maternal Adherence, Phase 3, Xhosa, attached 7/3/2013 
- DUDIT, Phase 3, 12PP, 21May2013, Xhosa, attached 7/2/2013 
- DUDIT, Phase 3, 12PP, 12May2013- clean, attached 7/2/2013 
- DUDIT, Phase 3, 6PP, 21May2013, Xhosa, attached 7/2/2013 
- DUDIT, Phase 3, 6PP, 12May2013- clean, attached 7/2/2013 
- DUDIT, Phase 2, 21May2013, Xhosa, attached 7/2/2013 
- DUDIT, Phase 2, 12May2013-clean, attached 7/2/2013 
- AUDIT, Phase 3, 6PP, 21May2013, Xhosa, attached 7/2/2013 
- AUDIT, Phase 3, 12PP, 21May2013, Xhosa, attached 7/2/2013 
- AUDIT, Phase 2, 21May2013, Xhosa, attached 7/2/2013 
- AUDIT, Phase 3, 12PP, 12May2013- clean, attached 7/2/2013 
- AUDIT, Phase 3, 6PP, 12May2013-clean, attached 7/2/2013 
- AUDIT, Phase 2, 12May2013-clean, attached 7/2/2013 
- Maternal Adherence & ART History, 13May2013, Xhosa, attached 7/2/2013 
- Maternal Adherence & ART History, 13May2013- clean, attached 7/2/2013 
- London Measure of Unplanned Pregnancy, 17May2013, Xhosa, attached 7/2/2013 
- London Measure of Unplanned Pregnancy, dated 17May2013, attached 7/2/2013 
 
The following changes included with the renewal were also approved: 
- MCH-ART Unanticipated Problems September 2015.pdf 
- Annual Review Approval Oct 2014.pdf 
 
Any proposed changes in the protocol must be immediately submitted to the IRB for review and approval prior to implementation, unless 
such a change is necessary to avoid immediate harm to the participants. Additionally, any unanticipated problems that involve risks to 
subjects must be reported to the IRB in accordance with the CUMC Unanticipated Problems: Reporting to the IRB of Unanticipated 
Problems Involving Risks policy. All submissions for modifications and unanticipated problems must be submitted through RASCAL. 
 
Renewal applications should be submitted 60 days before the expiration date of this study through RASCAL. Failure to obtain renewal of 
your study prior to the expiration date will require discontinuance of all research activities for this study, including data analysis. You 
must inform the IRB when your study has been completed via a Closure report in Rascal. 
 
If you have any questions regarding this approval, please call Diana Lesmes at (212) 342-3182 or Yaritza Collazo at (212) 305-1007. 




Yaritza Collazo, CIP 
Manager, IRB #3 
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Version  3.0 31 Oct 2013 
TITLE OF RESEARCH:
Strategies to optimize antiretroviral therapy services for
maternal & child health: the MCH-ART study




We are from the University of Cape Town
 
and ICAP at Columbia University. You are being asked to 
take part in a study that is being conducted at the
 
Gugulethu Midwife Obstetric Unit (MOU). The 
purpose of this study is to understand how to improve health care services for HIV-positive
 
women 
during their pregnancy and after they deliver the baby. 
 
 
We know that it is important for their own health as well as the health of their baby, that HIV-positive 
women receive the HIV care and treatment that they need both during and after delivery. Information 
learned in this study will help us to improve HIV services for pregnant women.
 
 
You are being asked to take part in this study because you are a pregnant woman who is HIV-positive
and you are getting your pregnancy care here at the Gugulethu MOU. The purpose of this consent is to 
give you information to help you decide if you want to take part in this study.
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will do the following at today’s visit: 
 Answer questions about your household, medical history, partnership status, HIV testing history
and disclosure status , family planning and previous use of HIV drugs
o If you are currently taking HIV drugs, we will ask you additional questions about HIV
and HIV drugs (including side effects and adherence).
 Have 5mLs (1 teaspoon) of blood drawn from your arm)
NOTE: The blood that is drawn today will be stored and used to check your viral load (this is the 
amount of HIV in your blood) at a later time. Results from these tests will not be available to you, the 
clinic, or the study staff. When the health care providers at the clinic need to check your viral load, they 
will take a separate blood specimen. When it is stored, your blood and test results will not have your 
name or any other way of identifying you attached to it. 
Review of medical records 
As part of this study, we will also be looking at and taking information from your antenatal, obstetric, 
ART clinic, laboratory and pharmacy records. From these records, we are interested in learning about 
the pregnancy care you received as well as information about your delivery. We also want to learn 
about the HIV care and treatment that you received during your pregnancy and after you delivered. 
Finally, we want to learn about your baby’s health status after delivery as well. 
All data that we review and abstract is confidential and no participant names are recorded on study 
documents. 
Contact for future study 
After the completion of this visit, it is possible that we will contact you again at your next clinic visit or 
at another time in the future to take part in additional research studies. At that time, you would be 
asked to review and sign another consent form. You can choose to not take part in any future studies if 
you are asked. You will be asked to provide contact information so that we may get in touch with you 
regarding additional research studies. Study staff will talk with you about the best way to contact you.  
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WHAT ARE THE POTENTIAL RISKS? 
If you decide to participate, you may feel uncomfortable about some of the personal questions you are 
asked about your health or your pregnancy. You may refuse to answer any question that you do not 
want to answer.  There is some risk in sharing personal and medical information.  We will be careful to 
keep all your information as private as possible.   
Drawing blood is normally done as part of routine medical care and presents a slight risk of discomfort. 
Experienced staff will draw blood under sterile conditions in order to protect you against these risks. 
WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study but if we identify any health care problem 
during the course of the study, we will make sure you are referred to the appropriate health care 
services. The information gained in this study may help to improve ART services for HIV-infected 
pregnant women in Cape Town, the Western Cape Province, and across South Africa. 
WHAT ARE THE ALTERNATIVES TO TAKING PART?  
The alternative to taking part in this study is to continue with your usual care at the MOU. 
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly confidential. 
Your name will not be written on the study forms and will not be used in connection with any 
information or lab specimens that are collected as part of the study.  
All study materials will be stored in locked filing cabinets. Only study staff and personnel involved in 
routine audits will have access to these materials. All staff involved in data collection and management 
will get specific training in confidentiality. 
Even with these procedures in place, if the study staff learns that you are a risk to yourself or someone 
else or of possible child abuse and/or neglect, study staff will tell the proper authorities. 
WILL I BE GIVEN ANYTHING FOR TAKING PART? 
No, there is no compensation for taking part in the study today. 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, or to 
withdraw from the study at any time without any penalty.  It will have no effect on the care that you 
receive at the Gugulethu MOU or any other health facility. 
FUTURE USE OF SPECIMENS: 
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If you agree, any  leftover  blood from the sample you have  provided for this research project  may be 
used for future HIV related research. It is possible that these stored samples may be tested to see if the 
HIV in your blood is resistant to any types of HIV medications or to look at other questions related to 
HIV. 
At this time, we cannot provide details of when this testing may be conducted. However, additional 
testing will not be done using these stored samples without the approval of the appropriate ethics 
committees involved in this research. 
If you agree to let us keep your stored samples for future research, they may be kept in a locked freezer 
for up to 5 years. If we do use your samples in the future, your name or other identifiers will not be 
included with this information (as with the rest of the information we collect for this study). 
Please initial below to indicate whether or not you give permission for your specimens to be used for 
future research. You may still remain in the study, no matter which you choose.  
______ (initial) I agree to have my blood stored for future research. 
______ (initial) I agree to have my blood stored for future research related to this study ONLY. 
______ (initial) I do NOT agree to the storage of my blood for future research. 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will provide 
it.  
Do you have any questions? 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you should 
contact: 
Dr Landon Myer Dr Elaine Abrams 
School of Public Health and Family Medicine ICAP, Columbia University 
Faculty of Health Sciences, University of 
Cape Town 
Mailman School of Public Health 
College of Physicians and Surgeons 
Tel: 021 406 6661 
Email: Landon.Myer@uct.ac.za 
Tel: +1 212 342 0543 
Email: eja1@columbia.edu 
If you have any questions about your rights as a research participant, you may contact the following 
member of the ethics committee: 
Prof Marc Blockman  Columbia University Medical Center IRB 
Chair, Human Research Ethics Committee Tel: +1 212 305 5883 
Faculty of Health Sciences, University of Cape 
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Town 
Tel: 021 406 6338 
CONSENT STATEMENT:   
I have read this form, or someone has read it to me.  I have been offered a copy of this consent form. I 
was encouraged and given time to ask questions.  I agree to be in this study.  I know that after choosing 
to be in this study, I may withdraw at any time.  My being in the study is voluntary. I understand that 
whether or not I participate will not affect my health care services received today, or at any time in the 
future. 
Please indicate your consent with your signature. 
Volunteer’s name ______________________________________ 
_______________________      ______________________________ 
Signature of Volunteer         Date 
Staff member’s name____________________________________ 
___________________________ __________________________ 
Signature of study staff  Date 
If the volunteer is unable to read or write the entire counselling process must be observed by an 
independent witness who can then confirm the procedure once the she has given consent. 
Fingerprint of volunteer: 
Witness: 
I confirm that I am independent of the study and that I witnessed the entire informed consent  
counselling process in the home language of the volunteer 
Witness’s name____________________________________ 
___________________________ __________________________ 
Signature of witness   Date 
Thank you. 
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1st half of 2nd 
Trimester 
N=245 






Gestational Age (weeks) <0.0001 0.03 0.36 
Term (≥ 37) 242 (87) 743 (77) 116 (71) 111 (76) 197 (80) 187 (81) 132 (75) 
Any Preterm (< 37) 36 (13) 217 (23) 48 (29) 34 (23) 49 (20) 43 (19) 44 (25) 
Late Preterm (34-37) 21 (8) 124 (57) 26 (16) 19 (13) 29 (12) 24 (10) 26 (15) 
Moderately Preterm (32-
34) 
13 (5) 70 (32) 16 (10) 9 (6) 16 (7) 11 (5) 18 (10) 
Very Preterm (28-32) 2 (0.7) 23 (11) 6 (4) 6 (4) 3 (2) 8 (3) 0 
Birthweight (grams) 0.03 0.19 0.3 
Normal (≥2500) 252 (91) 815 (85) 133 (81) 118 (81) 214 (87) 199 (87) 151 (86) 
Any LBW (<2500) 26 (9) 139 (15) 29 (18) 27 (18) 30 (12) 28 (12) 25 (14) 
LBW (<2500) 23 (8) 119 (12) 23 (14) 23 (16) 27 (11) 21 (9) 25 (14) 
 Very LBW (<1500) 3 (1) 20 (2) 6 (4) 4 (3) 3 (1) 7 (3) 0 




3120 (524) 3130 (574) 3145 
(532) 
0.89 0.27 
Size for Gestational Age (centile) 0.06 0.14 0.05 
LGA (>90th) 35 (13) 75 (8) 19 (12) 13 (9) 13 (5) 11 (5) 19 (11) 
AGA (10th – 90th) 211 (76) 750 (80) 124 (76) 105 (72) 201 (82) 190 (83) 130 (74) 
SGA (<10th) 31 (11) 111 (12) 17 (10) 22 (15) 25 (10) 22 (10) 25 (14) 
*  P values refer to comparisons between women who initiated ART before pregnancy vs during pregnancy (not expanded into the 4 time periods)
** P values refer to comparisons among women who initiated during pregnancy across the 4 time periods




Table 2.  Adjusted associations between HIV/ART status and adverse birth outcomes among women using TDF+FTC+EFV with live singleton births (n=961)  
 
Outcome Measure Comparison A* 
(Ref category: HIV-uninfected) 
Comparison B** 
(Ref category: Before pregnancy) 
Comparison C** 
(Ref Category: P1) 
 AOR [95% CI] P value  AOR [95% CI] P value  AOR [95% CI] P value 
Prematurity 
(<37 weeks) 
HIV-infected 1.97 (1.28–3.04) 0.002 During pregnancy 0.60 (0.39–0.94) 0.024 P2 0.89 (0.51–1.56) 0.694 
P3 0.79 (0.44–1.43) 0.441 
P4 1.43 (0.80–2.54) 0.223 
Low Birth Weight 
(<2500g) 
HIV-infected 1.51 (0.91–2.48) 0.107 During pregnancy 0.61 (0.36–1.02) 0.06 P2 0.67 (0.35–1.31) 0.243 
P3 0.68 (0.34–1.34) 0.263 




HIV-infected 0.96 (0.61–1.52) 0.869 During pregnancy 1.02 (0.55–1.90) 0.956 P2 0.77 (0.38–1.56) 0.461 
P3 0.74 (0.35–1.54) 0.414 
P4 1.62 (0.79–3.30) 0.184 
Comparison A (HIV-infected vs HIV-uninfected), Comparison B (ART initiated before pregnancy vs ART initiated during pregnancy), Comparison C (ART initiated during pregnancy 4 time points: P1 (<14 weeks), P2 (14-20 weeks),  
P3 (21-27 weeks), P4 (>28weeks) 
* adjusted for age, maternal height, parity and previous PTD 


























Gestational Age (weeks) 0.002 0.46 
Term (≥ 37) 242 (87) 19 (66) 18 (64) 1 (100) 
Any Preterm (< 37) 36 (13) 10 (34) 10 (36) 0 
Late Preterm (34-37) 21 (8) 6 (21) 6 (21) 0 
Moderately Preterm (32-
34) 
13 (5) 4 (14) 4 (14) 0 
Very Preterm (28-32) 2 (0.7) 0 0 0 
Birthweight (grams) 0.18 0.642 
Normal (≥2500) 252 (91) 24 (83) 23 (82) 1 (100) 
Any LBW (<2500) 26 (9) 5 (17) 5 (18) 0 
LBW (<2500) 23 (8) 5 (17) 0 0 
 Very LBW (<1500) 3 (1) 0 0 0 
Mean (SD) 3260 (548) 3016 (639) 0.0001 3002 (646) 3410 (-) - 
Size for Gestational Age (centile) 0.737 0.813 
LGA (>90th) 35 (13) 5 (18) 5 (18) 0 
AGA (10th – 90th) 211 (76) 20 (71) 19 (68) 1 (100) 
SGA (<10th) 31 (11) 3 (11) 3 (11) 0 
*  P values refer to comparisons between women who initiated ART before pregnancy vs during pregnancy (not expanded into the 4 time periods)
All the variables had <4% missing data, with similar proportions of missing data across the comparison groups
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Table 4.  Adjusted associations between HIV/ART status and adverse birth outcomes among women using PI-based regimen with live singleton births (n=29)  
 
Outcome Measure Comparison A* 
(Ref category: HIV-uninfected) 
 AOR [95% CI] P value 
Preterm Delivery 
(<37 weeks) 
HIV-infected 4.46 (1.55–12.83) 0.005 
Low Birth Weight 
(<2500g) 
HIV-infected 2.39 (0.67–8.57) 0.182 
Small for Gestational Age 
(<10th centile) 
HIV-infected 1.01 (0.26–3.92) 0.994 
Comparison A (HIV-infected vs HIV-uninfected)  
* adjusted for age, maternal height, parity and previous PTD 
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Gestational Age (weeks) 0.35 
Term (≥ 37) 205 (76) 18 (64) 135 (77) 
Any Preterm (< 37) 64 (24) 10 (36) 41 (23) 
Late Preterm (34-37) 37 (14) 6 (21) 26 (15) 
Moderately Preterm (32-
34) 
21 (8) 4 (14) 12 (7) 
Very Preterm (28-32) 6 (2) 0 2 (2) 
Birthweight (g) 0.85 
Normal (≥2500) 230 (86) 23 (82) 149 (85) 
Any LBW (<2500) 38 (14) 5 (18) 27 (15) 
LBW (<2500) 32 (12) 5 (18) 24 (13) 
 Very LBW (<1500) 6 (2) 0 3 (2) 
Mean (SD) 3135 (618) 3055 (646) 3068 (570) 0.59 
Size for Gestational Age (centile) 0.88 
LGA (>90th) 30 (11) 5 (19) 21 (12) 
AGA (10th – 90th) 203 (77) 19 (70) 134 (77) 
SGA (<10th) 30 (11) 2 (11) 20 (11) 
*  P values refer to comparison between women conceiving on ART on NNRTI regimens, PI regimens and those with missing regimen data 






Table 6.   Birth outcomes by HIV/ART status among women booking at <20 weeks with live singleton births (n=710) 
  



















Gestational Age (weeks)  0.005   0.64 
 Term (≥ 37) 116 (91) 454 (78)  165 (77) 289 (79)  
 Any Preterm (< 37) 12 (9) 127 (22)  49 (23) 78 (21)  
  Late Preterm (34-37) 8 (6) 73 (13)  27 (13) 46 (13)  
  Moderately Preterm (32-34) 3 (2) 41 (7)  19 (9) 22 (6)  
  Very Preterm (28-32) 1 (0.8) 13 (2)  3(1) 10 (3)  
        
Birthweight (g)   0.05   0.85 
 Normal (≥2500) 119 (93) 494 (85)  181 (85) 313 (86)  
 Any LBW (<2500) 9 (7) 85 (15)  32 (16) 53 (14)  
  LBW (<2500) 8 (89) 73 (86)  28 (88) 45 (85)  
  Very LBW (<1500) 1 (11) 12 (14)  4 (13) 8 (15)  
 Mean (SD) 3208 (535) 3026 (581) 0.001 3026 (588) 3026 (579) 0.99 
       
Size for Gestational Age   0.58   0.13 
 LGA 15 (12) 50 (9)  25 (12) 25 (7)  
 AGA 99 (77) 447 (79)  159 (76) 288 (81)  
 SGA 14 (11) 69 (12)  26 (12) 43 (12)  
       
*P values refer to comparison between HIV-infected and HIV-uninfected women 
**P values refer to comparisons between women who initiated ART before pregnancy vs during pregnancy (not expanded into the 4 time periods) 
All the variables had <4% missing data, with similar proportions of missing data across the comparison groups   
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Table 7. Adjusted associations between HIV/ART status and adverse birth outcomes among women booking at <20 weeks with live singleton births (n=710) 
Outcome Measure Comparison A* 
(Ref category: HIV-uninfected) 
Comparison B** 
(Ref category: Before pregnancy) 
Comparison C** 
(Ref Category: P1) 
AOR [95% CI] P value AOR [95% CI] P value AOR [95% CI] P value 
Preterm Delivery 
(<37 weeks) 
HIV-infected 2.75 (1.38–5.48) 0.004 During 
pregnancy 
1.18 (0.57–2.43) 0.655 P2 0.9 (0.51–1.60) 0.724 
Low Birth Weight 
(<2500g) 
HIV-infected 2.19 (0.97–4.94) 0.06 During 
pregnancy 




HIV-infected 1.05 (0.53–2.11) 0.884 During 
pregnancy 
0.94 (0.36–2.46) 0.895 P2 0.7 (0.32–1.50) 0.357 
Comparison A (HIV-infected vs HIV-uninfected), Comparison B (ART initiated before pregnancy vs ART initiated during pregnancy), Comparison C (ART initiated during pregnancy 4 time points: P1 (<14 weeks), P2 (14-20 weeks),  
P3 (21-27 weeks), P4 (>28weeks) 
* adjusted for age, maternal height, parity and previous PTD
** adjusted for age, maternal height, parity and previous PTD, CD4 count and VL
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